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GLOSSARY 
Allograft ·· transplantation between two individuals of the seme 
species. 
Autograft : transplantation in which donor and recipient are 
the same individual. 
ALS : anti-lymphocyte serum. 
Enhancement : specific antibody-mediated suppression of the 
cellular immune response to allografts; passive-: 
by administration of antibodies to the recipient ; 
active-: by antibodies formed by the recipient. 
Haplotype : set of genetic determinants located on a single 
chromosome. 
Histocompatibility ·. compatibility as determined by transplantation. 
Opsonization : process of coating an antigen which facilitates 
the phagocytosis of the antigen. 
Specificity (antigenici : antigenic determinant defined by the specific 
reaction with an antiserum. 
Xenograft : transplantation across a species barrier. 
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GENEFAL INTRODUCTION 
History 
Transplamtation as a method to replace irreversibly damaged tissues or 
organs has stimulated the imagination of man since a long time. In the 
years before 1900, several reports were published on successful trans-
plantation of animal or human tissue, mainly dealing with skin grafts. 
(Baronie, 1804; Bunger, 1823; Bert, 1863). 
In those days no distinction was made between the behaviour of auto-, 
alio-, or xenografts, which by itself can be regarded as an indication 
that the over-all results were very poor. Technically successful renal 
transplantation was first described in 1905 in dogs (Carrell and Guthrie, 
1905; Floresco, 1905). At best, the kidney grafts survived for 8 days, 
and this disappointing result was thought to be due to surgical 
complications. 
In subsequent years, it was noticed, that autografts could survive 
indefinitely, whereas alio- and xenografts ceased to function after 
several days. In 1944, Medawar described his experiments with repeated 
transplantations in rabbits. He showed that skin, grafted onto sensitized 
recipients, was rejected in an accelerated fashion. This "second-set" 
reaction proved that allograft rejection had em Immunological basis (the 
immunity theory, advanced in 1908 by Bashford et al.) and that it was 
not a lack of "growth substance" in the transplanted tissue that made it 
die (the "athrepsia" theory, advanced by Ehrlich in 1906). Medawar also 
observed that during the rejection episode the allografted tissue was 
heavily infiltrated by mononuclear cells. Mitchison showed in 1953 that 
the immunity to skin grafts could be transferred to another animal by 
injection of "sensitized" lymphoid cells, and not by injection of serum. 
Cellular mechanisms, therefore, were supposed to be of predominant 
importance in transplantation immunity (reviewed by Billingham and 
Silvers, 1963; and Brent and Medawar, 1967). Humoral immunity was 
thought to play a negligible role. 
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More recent experiments showed, however, that rejection could also be 
induced by transfer of serum from sensitized animals to recipients of 
organ or skin grafts (reviewed by Stetson, 1963; and by Carpenter, 
d'Apice and Abbas, 1976). Antibody-dependent rejection was readily 
induced in recipients of primarily vascularized organ grafts. Recipients 
of skin grafts were much more resistant to this form of rejection. This 
difference is due to the accessibility of the graft to antibody. It was 
shown (Gerlag et al., 1975) that skin allografts in the mouse become 
sensitive to the action of humoral factors such as antibodies only at 
day 4 or 5 after transplantation. 
Another prerequisite for the induction of antibody-mediated acute rejection 
of allografts is the presence of an active complement system (French, 
1972). In species like dog and rabbit, such an active system is present. 
In the mouse, the endogenous complement route is not activated efficiently 
enough by alloantibodies directed against the graft to evoke rejection. 
Acute rejection can only be induced in murine recipients if a heterologous 
effective complement, like rabbit or guinea pig complement, is administered 
along with the antiserum (Koene et al., 1973; Berden et al., 1977). 
In man, preformed antibodies can destroy an organ allograft in a hyper-
acute way, showing that alloantibodies are able to cause activation of 
the human complement system. This phenomenon was described first by 
Kissmeyer-Nielsen et al. (1966). 
Antibodies that are formed after transplantation can also harm renal 
allografts in man. Busch et al. (1969) associated chronic rejection with 
deposition of IgG on the vascular endothelium. This type of rejection is 
characterized by progressive intimai proliferation and vessel wall 
thickening with resultant ischemia (Kindcaid-Smith, 1967), and it is 
only seen if cellular mechanisms are depressed by immunosuppressive 
drugs. Chronic rejection by itself, however, responds very poorly to 
immunosuppressive therapy and accounts for a considerable amount of 
graft losses. It is thus obvious that antibody-mediated mechanisms can 
play an important role in graft destruction. 
Evidence has emerged from the field of tumor Immunology that antibodies 
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can be also active in graft protection. The initial observations were 
made in rodent tumor systems in the early 1900s (Flexner and Jobling, 
1907). When a non-viable fibrosarcoma was inoculated into rats some days 
before a challenge with viable tumor, the challenge inoculum, instead of 
regressing, grew progressively and this often led to the death of the 
recipient animal. 
Casey introduced the word "enhancing" for this phenomenon and showed 
that it had an immunological basis (Casey, 1934). It was found that 
enhancement was related to histocompatibility antigens (Snell, 1946) 
and that is was mediated by antibodies (Kaliss and Kandutsch, 1956) . Not 
only tumor grafts, but also grafts of normal tissue and organs (Billingham 
et al., 1956; Stuart et al., 1968) including skin grafts in mice (Jeekel 
et al., 1972; McKenzie and Snell, 1973) could be passively enhanced by 
alloantibodies. 
It is thus clear that both destruction and protection can be brought 
about by alloantibodies. The conditions that determine which of either 
phenomenon will occur in a given transplantation situation are not 
entirely clear. We have studied this problem in a mouse skin allograft 
model in which both antibody-mediated rejection and protection can be 
reproducibly induced. 
H-2 complex 
Regions & 
Subregions 
Loci: H-39 H-33 H-2K l a - l 
1 
I a - 2 I a - 4 l a - 5 I a - 3 S s - S l p H-2G H-2D H-2L pa-I H-31 9a-2 H-2T H-32 T l a 
Fig. 1. Genetic map of the H-2 complex and its vicinity. Only one locus for each region or subregion is shown. 
The loci are as follows: H-histocompatibility. Ia-I region-associated antigen. Ss-serum serological. 
Sip-sex-limited protein; Qa-Q region antigen; Tla-thymus-leukemia antigen. The order of H-2D, H-2L and 
of the T-region loci is not known; the arrangement shown is arbitrary (adapted from J. Klein et al., 
197Θ). 
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Traneplantation genetiae of the modela used 
The investigations described in this thesis were performed mainly in a 
mouse skin allograft model. In some of the experiments a mouse fibrosarcoma 
was used as the donor tissue. Donor and recipient mice were inbred and 
genetically well defined. The basic immunogenetics and immunobiology of 
the mouse major histocompatibility system, the H-2 complex, will not be 
discussed here, since excellent reviews are available (Klein, 1975; 
Festenstein and Démant, 1978). This system is very complex as a consequence 
of the polymorphism of the individual loci. However, to define the 
strain combinations and antisera used, and to determine the actual 
antigenic differences that give rise to the cellular and humoral immune 
responses in the recipients, the following inventarization has to be 
given. 
The genetic map of the H-2 complex, situated on chromosome 17, is shown 
in fig. 1. In this complex, several transplantation loci have been 
described. Transplantations across differences in these loci result in 
fast rejection of the graft in the case of a major locus incompatibility 
and in delayed rejection in the case of a minor locus incompatibility. 
The major histocompatibility loci are present in the K- and D-regions, 
and in the IA-subregion. A minor locus is present in the IC-subregion. 
Recently, another histocompatibility locus was reported to be present in 
the vicinity of the H-2D locus (McKenzie et al., 1977), which was called 
H-2L. The inbred mouse strains used in this study had the genotypes 
depicted in table I. In the H-2 hapiotype, a crossover is present 
between the IE- and IC-subregions. Using this strain as a recipient for 
B10.D2 or BIO.BR skin, the influence of parts of the H-2 complex in 
histocompatibility can be investigated. In the same combinations antibodies 
can be raised and the role of these antibodies in graft protection or 
destruction can be studied. To minimize non-H-2 differences, the B6AF1 
hybrid was raised from A/HeJ and C57B1 parents. The H-2 specificities, 
coded for by the K, D, and L-regions, which can be serologically detected 
on all cells in the different haplotypes used, are given in table II. 
B6AF1 mice carry the specificities both from A/HeJ and C57B1 mice. 
TABLE I 
Genotypes of the mouse strains used 
ι 
Strain H-2 haplotype K A B J E C S G D/L 
B10.D2 H-2 d d d d d d d d d d 
BIO.BR Н-2к k k k k k k k k к 
A/HeJ H-2 a k k k k k d d d d 
C57B1 Н-2Ь Ь Ь Ь Ь Ь Ь Ь Ь b 
TABLE II 
Serologically detectable H-2 antigenic specificities of the nouse strains used 
strain Haplotype Specificity 
- - 3 4 - 6 - 8 - - - 13 - - - - - - -
1 - 3 - 5 - 7 8 - 11 - - - - - - - - -
_ 2 - - 5 6 - - - - - - - - - - - - -
1 - 3 4 5 6 - 8 - 11 - 1 3 - - - - - - -
B10.D2 
BIO.BR 
C57 Bl 
A/HeJ 
H-2d 
H-2k 
H-2b 
H-2a 
Strain Haplotype Specificity 
B10.D2 
BIO.BR 
CS7 Bl 
A/HeJ 
H-2d 
H-2k 
H-2b 
H-2a 
_ _ _ 
23 24 25 
_ _ -
23 24 25 
27 28 29 - 31 - - 34 35 36 - - - 40 41 42 
27 28 29 - - - 33 - 35 36 - - 39 - - -
27 28 29 - - - - - 35 36 - - - 40 41 42 
Strain Haplotype Specificity 
B10.D2 
BIO.BR 
C57 Bl 
A/HeJ 
H-2d 
H-2k 
Н-2Ь 
H-2a 
43 44 - 46 47 49 - - - - - - - - -
- -45 - 47 49 - - 52 - - - - 60 -
_ _ -46 - - - - - 53 54 - 56 - 62 
43 44 45 - 47 49 - - 52 - - - - 60 -
TABLE III 
Ia antigene expreeeed by the тоиве β traine ueed 
Strain Haplotype Specificities 
B10.D2 
BIO.BR 
C57 BI 
A/HeJ 
H-2d 
H - 2
k 
H-2b 
H-2a 
-
1 
-
1 
-
2 
-
2 
- -
3 -
3 -
3 -
- 6 
- -
- -
- 6 
7 
7 
-
7 
8 - - 1 1 - - - 15 16 - -
- - - - - - - 15 - 17 18 
8 9 - - - - _ 15 - _ _ 
- - - - - - - 15 - 17 18 
Strain Haplotype Specificity 
B10.D2 
BIO.BR 
C57 Bl 
A/HeJ 
H-2d 
H-2k 
H-2b 
H-2a 
- -
19 -
- 20 
19 -
- - 23 
- 22 -
_ _ _ 
- 22 -
_ 
- W25 W26 
_ 
- W25 W26 
- W30 - - -
W28 - - 31 32 33 
- W29 W30 - - -
W28 - 31 32 33 
TABLE IV 
Specifitiee recognized in the strain combinations 
Donor Recipient H-2 antigens la antigens 
B10.D2 B6AF1 31, 34 11, 16, 23 
BIO.BR B6AP1 7, 32 
-19-
The I-region associated specificities, the socalled la antigens, are 
listed in table III. la antigens are present mainly on B-lymphocytes, 
seme T-lymphocytes, and on macrophages. 
The specificities that are recognized in the combinations used are 
shown in table IV. In B6AF1 anti B10.D2 serum, antibodies against H-
2Κ.31 and 34, and against la.11, 16 and 23 гиге present. The H-2K.34 
specificity is probably an la specificity (Staines et al. 1976). 
The B6AF1 anti BIO.BR serum contains antibodies against H-2 specificities 
7 and 32. H-2.32 is coded for by the D region of the H-2 complex; H-2.7 
is coded for by the G region. Antigens that are coded for by this latter 
region are expressed on the membranes of erythrocytes and do not play an 
important role in histocompatibility. Thusfar no antibodies against la 
antigens have been raised in this combination. 
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Enhanoement and acute rejection of mouse зкіп allografts 
The experimental conditions for the reproducible induction of acute 
antibody-mediated rejection and passive enhancement were established 
in the B10.D2 •* B6AF1 model (Koene et al., 1973). Both antibody-mediated 
effects could be elicited by administration of the same B6AF1 anti 
B10.D2 serum. Passive enhancement can be induced by administration of 
0.25 ml alloantiserum on days 0, 2, and 4 after transplantation; acute 
rejection is evoked by administration of 0.25 ml alloantiserum to ALS-
immunosuppressed recipients, along with 0.25 ml rabbit serum as a 
source of complement on day 7 after transplantation. 
Attempts to separate the enhancing and destructive activities in the 
serum by using physicochemical methods failed (Jansen et al. 1975a). 
Neither was it possible to make a separation by isolating pure IgG 
subclass proteins (Jansen et al., 1975b). Antibodies that were exclu­
sively enhancing could be isolated when they were purified on the basis 
of the specificity against which they were directed (Jansen et al., 
1975c). Antibodies directed against la antigens showed unimpaired enhancing 
activity in comparison to the unfractionated alloantiserum, but were 
unable to induce acute rejection. To prepare these anti-la antibodies, 
advantage was taken from the fact that red blood cells do not carry I-
region products on their membranes. By absorption with red blood cells 
from the donor strain, antibodies directed against products of the K-
region were removed. Along with this procedure, the destructive activity 
vanished. 
Although these studies gave a better insight into the mechanisms of 
antibody-mediated graft destruction and protection, several questions 
remained unanswered, and some new problems were raised. These formed the 
basis of the current investigation and they are described in detail in 
the following paragraph. 
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Aim of this study 
The first question that was raised from the results of the previous 
studies concerned the activity of anti H-2K and anti H-2D antibodies in 
enhancement and acute rejection. To test the in vivo activities of these 
socalled SD (serologically defined) antibodies, an isolation procedure 
had to be designed. 
A method for the elution of anti H-2K and H-2D antibodies from murine 
blood platelets was described in brief by Colombini et al. (1976). 
Staines et al. (1976) described a procedure for the elution of anti SD 
antibodies from murine erythrocytes. In this latter protocol, the eluted 
antibodies were purified by ammonium sulphate precipitation and used for 
in vitro serologic testing. We found that the antibodies isolated in 
this way were not suited for in vivo injection due to the considerable 
release of hemoglobin during the elution procedure. In chapter 1, a 
method is described for the elution of anti H-2K antibodies from murine 
red blood cell ghosts. In this way, disturbing hemoglobin release during 
the elution step is diminished, and the eluate is, after another 
purification step, suitable for in vivo testing. 
The in vivo testing of the isolated anti SD antibodies is described in 
chapter 2. Both anti H-2K and H-2D antibodies were tested for their 
destructive and protective activities on murine skin allografts. 
A second question that was raised concerned the practical usability of 
enhancing antibodies. Large scale production of these antibodies will be 
necessary, before they can be used in clinical treatment protocols. The 
preparation of anti la sera by absorption with red blood cells is very 
cumbersome. Large amounts of red blood cells or platelets of defined H-2 
phenotype are required. During elution potentially pathogenic immune 
complexes might be released. To be able to prepare antibody fractions of 
defined specificity on a larger scale, other techniques have to be 
developed. 
A possible method of purification is affinity chromatography on immobilized 
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transplantation antigens. If It were possible to isolate and purify H-
2K, D antigens, and to couple them covalently to a carrier particle, the 
antigen could be used as an immunoabsorbent to prepare la antisera. 
To test the practical usefulness of such a purification procedure we 
tried to purify B6AF1 anti B10.D2 antiserum on an affinity column of 
coupled B10.D2 transplantation antigens. We used the detergent NP-40 to 
solubilize the H-2 antigens from mouse lymphocytes, according to the 
procedure described by Schwartz and Nathenson (1971). 
We will not discuss here the structure of the products of the K, D, and 
I regions; an extensive review on this subject was recently published by 
Vitetta and Capra (1978). 
In chapter 3 the isolation, purification and coupling of transplantation 
antigens is described. The in vitro and in vivo activities of the 
antibodies eluted from the antigen column are also described in this 
chapter. 
Up till now we concentrated on the preparation of enhancing antiserum 
fractions by attempts to separate the antibodies on the basis of their 
distinct antigen-binding specificities. Another, and possibly even 
simpler, approach might be to change the antibody molecules themselves 
in such a way that they would loose their destructive capacity with 
preservation of the enhancing activity. This goal might be accomplished 
by the use of F(ab')2 fragments of antibodies. These fragments can be 
prepared from IgG by renoval of the Fc part (fig. 2). 
The results of Koene et al. (1973), Gerlag (1975) and Berden et al. 
(1977), suggest that the activation of the classical pathway of the 
complement system is of major importance in the induction of the acute 
rejection phenomenon, although there are some indications (Berden, 
unpublished) that complement-independent mechanisms can play a role. 
Since activation of the classical complement route occurs via the binding 
of the first complement component, Clq, to the Fc part of the IgG 
molecule, we assumed that it would not be possible to evoke acute 
rejection by administration of F (ab')2 fragments. It was known already 
that F(ab')2 fragments lack in vitro complement-dependent cytotoxicity. 
N-terminus 
Ν-terminus 
Г , 1 ., Г У 1 гГ| С-terminus 
С- terminus 
Fig. 2. A typical IgG molecule. The cleavage by proteolytic enzymes 
occurs in the hinge-region, resulting in the formation of 
F(ab) or F(ab')2 fragments. 
In the lower part of the figure, the number of amino acids 
in typical domains is shown. 
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The antigen-binding site of the IgG molecule is unaffected by the removal 
of the Fc-fragment. It is, therefore, likely that administration of 
F(ab*)2 fragments to recipients of allografts will result in the covering 
of graft antigens with F (ab')2 fragments. 
The diminished accessibility of the graft to the host's cellular defense 
mechanisms as the result of masking of donor transplantation antigens in 
this way, was regarded as a possible mechanism of enhancement. 
On the basis of these assumptions, F[ab')2 fragments would have enhancing 
activity comparable to intact IgG, but lack the capacity to evoke acute 
rejection. We decided therefore, to prepare these fragments and test 
their in vitro and in vivo activities. The results obtained in the skin 
allograft model are described in chapter 4. 
A model in which enhancing activity of F(ab')2 fragments actually was 
reported is tumor allotransplantation in mice (Kaliss et al., 1976). As 
this finding was not in agreement with the results obtained by us in the 
skin allograft model, we decided to test the effects of similarly 
isolated and purified F(ab')2 fragments in a tumor allograft model. 
This model was developed during this study, and proved to be very 
suitable for the determination of putative enhancing activity, since 
graft protection leads in this model to progressive growth of the tumor. 
The in vivo effects of F(ab')2 fragments on tumor allografts are des-
cribed in chapter 5. 
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Chapter 1 
PROCEDURE FOR THE ISOLATION OF MOUSE ANTI H-2 ANTIBODIES 
FROM COMPLEX ALLOANTISERA 
R.W.M. de Waal and R.A.P. Koene 
From the Department of Medicine, Division of Nephrology, 
University of Nijmegen, Nijmegen, The Netherlands 
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B6AF1 anti B10.D2 ascites fluid was incubated with donor strain red 
blood cells to absorb the anti H-2 antibodies. The antibody-coated RBC 
were then lysed, and from the ghosts the antibodies were eluted. This 
anti H-2 preparation was further purified by affinity chromatography, 
using an immobilized anti IgG2 antiserum. Thus a pure anti H-2 IgG2 was 
obtained for in vitro and in vivo testing. 
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Many mouse alloantisera have been shown to contain antibodies directed 
against at least two different groups of transplantation antigens. These 
antigens are encoded by genes in the К and D regions and the I region of 
the major histocompatibility complex (MHC), respectively. They differ in 
tissue distribution, molecular weight and function. Antibodies against 
I region associated antigens (la antigens) can be isolated from complex 
alloantisera by absorption with mouse red blood cells, that carry the 
H-2K and H-2D antigens but lacle la antigens. By such absorption anti-H-2K 
and H-2D antibodies are removed from the sera. There is recent evidence, 
that these purified anti la sera can induce specific immunosuppression 
leading to prolonged or even indefinite survival of allografts in 
several transplantation models (Davies et al., 1974; Staines et al., 
1974; Jansen et al., 1975a). This phenomenon is called immunologic 
enhancement. It is of great interest to test also the activity of pure 
preparations of the anti-H-2K and H-2D antibodies, that remain absorbed 
onto the erythrocytes. In vitro and in vivo studies show (Jansen et al., 
1975a) that these antibodies play a role in graft destruction at the 
efferent arc of the immune response. However, studies of Staines et al. 
(1975) suggest that they might have some enhancing activity. 
To test this, pure preparations of anti H-2 antibodies, uncontaminated 
by anti la antibodies are required. We present here a method for the 
elution of a pure anti H-2 lgG2 antibody fraction from mouse erythro­
cytes, which is suitable for in vitro and in vivo testing. The lgG2 
subclass is chosen because antibodies of this subclass can induce 
enhancement as well as accelerated graft destruction (Jansen et al., 
1975b). 
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MATERIALS AND METHODS 
Alloantieemm 
Inbred strains of B10.D2 n/Sn(H-2 ) mice were originally obtained from 
the Jackson Laboratory (Bar Harbor, Maine). C57B16/RÌJ (H-2 ) and 
A/HeJ(H-2 ) mice were obtained from the Radiobiological Institute 
(Rijswijk, The Netherlands). In our animal laboratory, these mouse 
strains were kept by brother-sister matings. (C57B16 / Rij χ A/HeJ)Fl 
(»B6AF1) hybrids were produced in the laboratory. The alloantiserum was 
prepared by injecting, intraperitoneally, B6AF1 mice at weekly intervals 
with 5 X 107 B10.D2 lymphoid cells obtained from spleen, thymus and 
lymph nodes, made into a suspension in complete Freund's adjuvant (equal 
volumes of suspension and adjuvant). After five injections, the mice 
developed ascites and could be tapped every 1 to 2 weeks. The cytotoxic 
titer of the ascites fluid was the same as the titer in the serum of 
these mice. Antisera were stored at -20 С This antiserum contains 
antibodies directed against the К and I regions of the MHC and we have 
previously shown that after removal of the anti H-2K antibodies the 
enhancing capacity of this serum remains unimpaired (Jansen et al., 
1975a). 
Affinity ohromatography 
Specific antiserum against mouse 7S IgG2 was coupled to cyanogen bromide-
activated Sepharose 4B (Pharmacia) according to the following procedure: 
6 ml of specific antiserum were mixed at room temperature with an equal 
volume of saturated ammonium sulphate (SAS) at pH 6.5. The resulting 
precipitate was washed three times with 50% SAS dissolved in 6 ml 0.1 M 
ЫаНСОз and 0.5 M NaCl, and dialysed against the same solution overnight. 
The ratio of CNBr-Sepharose and protein that would give optimal adsorption 
capacity was determined by coupling protein, precipitated from 6 ml 
antiserum (dissolved in 6 ml 0.1 M ЫаНСОз 0 · 5 M NaCl) to 0.75, 2.0, and 
4.0 g CNBr-Sepharose respectively. Although 4 g CNBr-Sepharose 4B 
coupled far more protein, the adsorption capacity appeared almost nil. 
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Best results were obtained with 0.75 g CNBr-Sepharose 4B. This amount 
was swollen on a glass filter and washed for 15 min with 10~3.M HCl. 
Thereafter, protein (about 100 mg) was coupled to the gel under gentle 
stirring. Coupling was completed in 2h. Uncoupled protein was mixed 
twice more with the same quantity of activated Sepharose 4B. After 
coupling, any remaining active groups in the gel were inactivated by 
incubating the gel with 1 M ethanolamine at pH Θ.0 for 1 h. To remove 
the non-covalently adsorbed protein after coupling, the gel was washed 
following a modification of van Munster's method (Van Munster, 1972), 
successively with (a) 0.1 M borate buffer at pH Θ.0 + 1 M NaCl, (b) 
0.1 M citrate buffer at pH 6.0., and (c) 0.05 M citrate buffer pH 2.6 + 
1 M NaCl. Thereafter, the gel was equilibrated with 0.05 M citrate 
buffer at pH 6.0. The Sepharose carrying the antibodies was packed in 
jacketed glass columns (2.6 χ 10 on), cooled with tap water. 
Serology 
Tn vitro cytotoxic activity was measured with B10.D2 and C3H/He lymphoid 
cells using the trypan blue dye exclusion method (Gorer and О'Gorman, 
1956). The C3H/He strain was chosen to test the specificity of the allo-
antiserum. This strain has the haplotype H-2 and bears no antigenic 
determinants, against which the alloantiserum is directed. One tenth 
milliliter of spleen cells, prepared free of red cells with Tris-NH^Cl 
(5 χ 106 cells/ml), was incubated in tubes with equal volumes of 
antibody dilution and rabbit complement for 30 min at 37 C. Percentages 
of lysed cells were read microscopically. 
RESULTS AND DISCUSSION 
Abaorption procedure 
B10.D2 red blood cells (RBC) were purified from blood by the following 
procedure: 100 ml of freshly drawn blood, collected in CPD medium, were 
centrifuged at 700 g for 20 min, and the supernatant and buffy coat were 
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discarded. The pellet was washed three times in 0.16 M phosphate buffered 
saline at pH 7.2. Thereafter the RBC were further purified by passage 
through a closely packed cotton wool column (20 χ 4 cm) as described by 
Diepenhorst et al. (1972). In this way, more than 99% of leukocytes and 
platelets were removed. Ten milliliters of full antiserum (IgG2 content 
4 mg/ml) were absorbed with these purified RBC during 2 h at room 
temperature in sealed tubes, rotating end over end at 15 rpm. 
Recovery procedure 
After incubation the RBC were recovered and washed extensively with PBS. 
To avoid disturbing haemoglobin release during the elution procedure, 
the RBC were first lysed by mixing with a Tris-NH^Cl solution. The IgG 
carrying ghosts were precipitated by centrifugation (22,000 g, 10 min), 
washed and resuspended in elution buffer, consisting of 0.05 M citrate 
buffer pH 2.6 and 1 M NaCl. The ghosts were precipitated by centrifugation 
and the supernatant was recovered and quickly brought to pH 7.4. The 
eluate was concentrated by ultrafiltration (Amicon ultrafiltration 
membrane XM-50), and dialysed overnight against 0.05 M citrate buffer pH 
6.0 which served as the starting buffer for affinity chromatography. 
The dialysed eluate was applied to the anti IgG2 column in portions of 3 
ml. The column was washed with 0.05 M citrate buffer, pH 6.0, at a flow 
rate of 30 ml/h, to remove unbound material. Adsorbed protein was 
eluted with 0.05 M citrate buffer pH 2.6, containing 1 M NaCl. The 
protein containing eluate was collected Immediately in 0.25 Tris-BCl 
buffer at pH 8.6, to avoid loss of biologic activity. A typical elution 
pattern is shown in fig. 1. Before use, all fractions were equilibrated 
in saline by dialysis, concentrated by ultrafiltration, and sterilized 
by means of membrane filtering (Sartorlus Membran Filter SM 11306, 
G<5ttingen. West Germany). The IgG2 content of the final preparation was 
10 pg/ml. 
The yield of the described procedure is about 0.1 mg of protein per 
50 ml of packed RBC. immunodiffusion showed the preparation to contain 
only antibodies of the IgG2 subclass. Pig. 2 shows the cytotoxic activity 
of the eluted antibodies as a function of dilution. It can be seen that 
120 
Τ г 
160 
volume (ml) 
Fig. 1. Part of an e lu t ion p r o f i l e obtained by the separation of mouse 
IgG2 from mouse a n t i H-2K IgG, eluted from mouse red blood c e l l 
ghosts . At (a) bound prote in i s e lu ted . At (b) the column i s re-
equi l ibrated with s t a r t i n g buffer. 
π Ι ι Γ 
32 64 12Θ 256 512 1024 2046 4096 8192 
С dilution)" 
Fig. 2. Cytolysis of B10.D2 spleen cells by anti H-2K IgG2, in the 
presence of rabbit complement. The undiluted preparation 
contained 10 ug of IgG2/ml. 
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90% cytotoxicity is obtained. This is in contrast to the results with 
anti la sera, which usually react only with В cells that make up 45 4 
of the splenic lymphocyte population. The specificity of the anti-SD 
IgG2 was tested on C3H/He lymphoid cells. No cytotoxic activity towards 
these cells could be observed and this showed that the cytotoxicity of 
the anti SD IgG2 was directed specifically to H-2 antigens of the H-2 
haplotype. The preparation can be used for intravenous injection into 
mice. We found that the removal of hemoglobin by washing before elution 
was a critical step in the procedure. If this was not done, the eluate 
contained large amounts of hemoglobin that were difficult to remove. The 
hemoglobin-containing eluate could not be used in vivo because, due to 
its toxicity, all mice died after intravenous injection. However, removal 
of hemoglobin and affinity chromatography on the anti-IgG2 column resulted 
in a non-toxic preparation. In vivo results obtained with this eluted 
fraction will be reported separately. 
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The enhancing and destructive effects of anti H-2K and anti H-2D 
antibodies (socalled SD antibodies) were studied in B6AF1 recipients of 
B10.D2 or BIO.BR skin allografts. The SO antibodies were isolated from 
B6AF1 anti B10.D2 and B6AF1 anti BIO.BR alloantiserum by adsorption to 
donor strain red blood cells and subsequent elution. Acute antibody-
mediated rejection of B10.D2 or BIO.BR skin grafts was readily induced 
by administration of anti H-2K or H-2D antibodies, respectively, along 
with rabbit complement. 
Treatment of the B6AF1 recipients with the antibody eluates on day 0, 2, 
and 4 after transplantation resulted in specific and significant 
prolongation of graft survival. 
Both graft destruction and enhancement can therefore be mediated by 
antibodies directed against the same SD specificity. 
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Alloantisera directed against products of the Major Histocompatibility 
Complex of the mouse (the H-2 complex) can influence the fate of organ 
or tissue allografts in two opposite ways. Destruction as well as 
protection of the graft can be induced by the same alloantiserum in a 
mouse skin transplantation model. Administration of B6AF1 (H-2 ) anti 
B10.D2 (H-2 ) antiserum to B6AF1 recipients of B10.D2 skin grafts at 
days 0, 2, and 4 after transplantation prolongs graft survival from 10.4 
to 18.9 days, whereas intravenous injection together with rabbit complement 
at day 7 or 10 in immunosuppressed recipients results in acute antibody-
mediated rejection (AAR) of the graft (1), a phenomenon similar to 
hyperacute rejection in human renal transplantation. Attempts to separate 
the protective and destructive antibodies by physicochemical methods (2) 
or by isolation of pure subclasses of IgG (3) failed. It was shown by 
Staines et al. (4) that absorption of an enhancing mouse alloantiserum 
with donor strain erythrocytes yielded an antiserum directed against I 
region determinants which had unimpaired enhancing capacity. Jansen et 
al. (5) found that anti la IgG2, prepared by absorption of B6AF1 anti 
B10.D2 IgG2 with B10.D2 erythrocytes, was unable to cause AAR, whereas 
its enhancing capacity was equal to that of unabsorbed B6AF1 anti BIO.02 
IgG2. It is obvious from these results that anti la antibodies play an 
important role in enhancement. 
By these absorptions with B10.D2 red blood cells, antibodies directed 
against H-2K region products were removed along with the destructive 
activity, which suggests that an anti H-2K serum can cause AAR. To test 
this, the antibodies absorbed to the donor strain erythrocytes have to 
be eluted and purified. An isolation procedure for anti H-2K.31 eluates 
was described earlier (6). In this paper evidence is produced that by 
administration of H-2K as well as H-2D antibodies AAR can be induced. 
Using an anti H-2K or D antibody eluate, the role of these socalled SD 
(serologically defined) specificities in enhancement can be studied in 
the same transplantation model. In the literature contradictory reports 
can be found on the activity of anti SD sera in enhancement. In mouse 
skin allograft models, enhancement is difficult to achieve by admini­
stration of red blood cell eluates (7) or by anti SD sera raised in 
congenie recombinant mouse strain combinations (Θ). In other transplantation 
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models, however, enhancement can be induced with anti SO sera. This was 
reported for mouse tumor (9) and heart (10) allografts, and for rat 
kidney allografts (11). On the contrary. Catto et al. (12) could not 
induce enhancement of rat kidney allografts with an anti SD serum. 
Recently, McKearn et al. (13), using monoclonal anti Ag-B A antibodies, 
found preliminary evidence that these sera could induce enhancement of 
rat kidney allografts. 
There can be no doubt that in several models enhancing activity of anti 
SD sera has been demonstrated. In mouse skin allograft models, however, 
only marginal prolongations have been reported (7, 8). In the current 
study, evidence is presented that administration of H-2K and H-2D 
antibody eluates caused significantly prolonged survival of mouse skin 
allografts, demonstrating that, apart from their destructive activity, 
anti SD antibodies can also induce immunologic enhancement. 
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MATERIALS AND METHODS 
Animale 
Inbred atraina of B10.D2/new SN (H-2 ), A/HeJ (H-2a), СЗН/HeJ (H-2k) and 
BIO.BR (H-2 ) mice were originally obtained from the Jackson Laboratory 
(Bar Harbor, Maine). Balb/c (H-2 ) mice were obtained from the National 
Inatitutea of Health, Betheada, Maryland. C57B1/Rij (H-2 ) mice were 
obtained from the Radiobiological Inatitute TNO, Rijawijk, The Netherlanda. 
(C57B1/Rij χ A/HeJ)Fl (=B6AF1) hybrida (Н-г*5*) were raiaed by brother-
aiater matings. 
Comp lement 
Fresh frozen serum fron New Zealand white rabbits was used as a source 
of complement. The rabbit aera were preselected, and only those sera 
that lyaed 10% or less of mouse lymphocytes in the absence of allo-
antibody were used. 
Antiaera 
B6AF1 anti B10.D2 and B6AF1 anti BIO.BR ascites fluids were raised as 
described (6). B6AF1 anti B10.D2 antibodies are directed against the H-
d d 
2K specificity 31 and the la specificities 11, 16 and 23. B6AF1 anti 
BIO.BR is directed against Η-2D specificity 32; although there is a 
difference at the 1-е region in this combination, no known anti la 
activity is present in this serum (14). Anti lymphocyte serum (ALS) was 
raised in goats by i.m. injections of C57B1/RÌJ lymphocytes (15). 
Analytical procédures 
The amount of IgG2 in alloantisera and anti SD eluates was determined by 
radial immunodiffusion using anti IgG2 serum and mouse immunoglobulin 
standard fron Meloy (Springfield, Va.). The amount of protein was 
guantitated by the method described by Lowry et al. (16). 
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Absorption procedure 
Anti SD sera were prepared by absorption of complex alloantisera with 
pure red blood cells (RBC) carrying histocompability antigens of the 
donor haplotype according to a modification of the procedure described 
in a previous paper (6). 
Anti H-2K.31 antibodies were prepared by absorption of B6AF1 anti B10.D2 
serum with B10.D2 or Balb/C erythrocytes; anti H-2D.32 antibodies were 
prepared by absorption of B6AF1 anti BIO.BR serum with BIO.BR or C3H/HeJ 
RBC. Freshly drawn blood from 200 mice, collected in 8 ml portions in 
3 ml anticoagulant citrate buffer, was centrifugea for 5 min at 2000 g 
о 
at 4 С. The supernatant and buffу coat were discarded. The pelleted RBC 
were washed three times in phosphatebuffered saline (PBS) at pH 7.4; 
after each centrifuge run the buffу coat was carefully removed. There­
after the RBC were purified further by passage through a closely packed 
cotton wool column (20 χ 4 cm) as described by Diepenhorst et al. (17). 
In this way, more than 99% of leukocytes and platelets were removed. The 
purity of the RBC was controlled by examination of May-Grunwald-Giemsa 
stained smears of the column eluate. Only RBC suspensions containing 
less than 1 leukocyte per 105 erythrocytes were used. After passage 
through the column the RBC were washed once more with PBS, centrifugea 
at 200 g for 5 min, resuspended in the same volume of 0.125% glutaraldehyde 
in PBS, and incubated for 45 min at 4 С. 
By this procedure, the cells are fixated, which reduces loss of antigen-
antibody complexes during the subsequent incubation with alloantiserum, 
and cell lysis during the elution procedure. Glutaraldehyde was removed 
in two washings and the packed RBC were incubated overnight at 4 С in 
an equal volume of 2% (v/v) normal B6AF1 serum in PBS. In this way 
nonspecific absorption of protein during the subsequent incubation with 
antiserum was prevented. The RBC were then pelleted by centrifugation 
(5 min, 2000 g) and resuspended in an equal volume of 50% (v/v) of the 
appropriate alloantiserum in PBS. 
Absorption was completed in 1 hr at room temperature under gentle 
shaking. 
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Elution procedure 
After the absorption, the RBC were pelleted by centrifugation (5 min, 
2000 g) and washed five times with five volumes of PBS. The RBC were 
then quickly suspended in five volumes of elution buffer, consisting of 
1% (w/v) bovine serum albumine in 0.1 M glycine buffer at pH 2.7. The 
RBC were centrifugea at 2000 g for 5 min, the supernatant was taken and 
neutralized immediately to pH 7.4. with 2M Tris solution. A precipitate 
that formed during neutralization was removed by centrifugation (20 min. 
2000 g). 
Purification of eluted IgG 
IgG was purified from the eluted fraction by absorption to protein-A-
sepharose 4B (Pharmacia, Uppsala, Sweden). The eluate was absorbed 
о 
batchwise overnight at 4 C. Elution was performed with 0.05 M citrate 
buffer at pH 2.6, containing 1 M NaCl. The protein-containing eluate was 
neutralized immediately with 2 M Tris solution, dialyzed overnight 
against PBS, concentrated to a volume of 10 ml by ultrafiltration and 
sterilized by passage through a sterile 0.2 μ membrane filter. The 
resulting anti SD preparations contained about 600 ug of protein per 
ml and 5-10 ug IgG2 per ml. 
Cytotoxicity аввау. 
The in vitro cytotoxic activity of alloantisera and eluted fractions was 
determined in a lymphocytotoxicity assay as described (6). 
Skin grafting 
Transplantation of B10.D2 and BIO.BR tail skin onto B6AF1 recipients was 
carried out as described earlier(15). The median survival time and the 
standard deviations were calculated according to the method of Litchfield 
(18). 
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Разві е enhancement 
Male B6AF1 recipients of a B10.D2 or BIO.Br skin graft were treated on 
days 0, 2, and 4 after transplantation with 0.25 ml of whole alloantiserum 
or with different doses of anti SD eluate, injected i.p. Control aniñáis 
received 0.25 ml of PBS. 
Acute antibody-mediated resection (AAR). 
Female B10.D2 or BIO.BR tail skin was grafted onto female B6AF1 recipients. 
The survival of these grafts was prolonged by the injection of 0.25 ml 
ALS, i.p., on days 0, 2, and 4 after transplantation. Rejection of the 
skingrafts caused by cellular mechanisms is postponed by this treatment 
to day 25-30 after grafting. On day 7, recipient mice were injected i.v. 
with different doses of anti SD eluate or alloantiserum along with 
rabbit complement. AAR was defined as complete necrosis of the skin 
graft, ocurring within 24 to 72 hr after i.v. injection. 
RESULTS 
The in vitro properties of the anti H-2K and H-2D preparations are shown 
in table I. In the eluates very low amounts of IgG2 are present, however 
with a high specific activity. Since lgG2 is the major complement-fixing 
subclass of IgG in the mouse, and therefore accounts for the greater 
part for the in vitro cytotoxic activity of the anti SD eluates, specific 
activity was expressed per yg of IgG2. 
The in vivo activities of the anti H-2K and H-2D eluates in acute 
antibody-mediated rejection are shown in table II. AAR was readily 
induced both by i.v. injection of anti H-2K and H-2D antibodies in B6AF1 
recipients of the appropriate skin allografts, along with rabbit 
complement. The table shows that by a dose as low as 1 ug of anti H-
2K.31 IgG2, AAR of B10.D2 skin could be induced. In the control re 
recipients, treated with anti SD antibodies directed against the 
irrelevant specificity, no AAR was observed. 
TABLE 1 
In vitro properties of the anti H-2K and H-2D RBC eluates compared to the corresponding alloantisera 
Source of 
antibody 
Protein content 
(mg/ral) 
Concentration of 
IgG2 (ug/ml) 
Cytotoxic 
titer 
Specific 
activity 
Purification 
factor 
B6AF1 anti B10.D2 serum 32.8 5300 1:128 24.2x10 
Anti H-2K eluate 0.7 10 1:128 12.8 500 
B6AF1 anti B10.BR serum 34.6 5000 1:32 6.2x10 
A n t i H-2D e l u a t e 0.5 1:64 12.8 2,000 
a -1 
Specific activity was defined as (cytotoxic titer) per vg IgG2. 
h> . _. . . _ . , ,. . specific activity in the eluate 
Purification factor was defined as -*•—г-=-. . . . .•'—;—т-г Ζ -; Π ΖΊ 
specific activity in the whole alloantiserum 
TABLE I I 
Activity of the anti H-2K and H-2D eluatea in acute antibody-mediated rejection of establiehed ekin grafie in B6AF1 reaipienta 
Donor 
(hapïotype) Treatment 
Specificity 
recognized 
Dose of 
IgG2 (pg) 
No. of 
recipients AAR 
B10.D2 (H-2 ) 
BIO.BR (H-2 ) 
anti H-2K 
anti H-2D 
anti H-2D 
anti H-2K 
31 
32 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Recipients were injected i.v. on day 7 after transplantation with the eluate, along with 0.25 ml of rabbit serum, as a 
source of complement. 
+ indicates complete necrosis of the skin graft within 48 to 72 hr after i.V. injection of the eluate plus rabbit complement. 
TABLE III 
Activity of the anti B-2K and H-2D eluatea in erihanoement of skin allografts in B6AF1 recipients 
Donor 
(haplotype) Treatment 
Dose of 
IgG2 (wg) 
No. of 
recipients 
MST SD 
B10.D2 (H-2 ) 
B10.BR(H-2 ) 
none 
PBS, 0.25ш1хЗ 
anti H-2K, 0.25mLx3 2.5x3 
anti H-2K, 0.40mlx3 4.0x3 
B6AF1 anti B10.D2 serum, 0.10mlx3 500 x3 
anti H-2D, 0.40mlx3 2.0x3 
none 
PBS, 0.25mlx3 
a n t i H-2D, 0.40mlx3 2.0x3 
B6AF1 a n t i BIO.BR serum, 0.25mlx3 1250 x3 
a n t i H-2K, 0.50тЬсЗ 5.0x3 
10 
9 
10 
13 
10 
6 
10 
10 
5 
23 
6 
10.4 
10.4 
12.4 
14.4 
18.9 
10.4 
14.7 
15.1 
16.9 
17.4 
13.8 
1.04 
1.04 
1.06 
1.05 
1.06 
1.10 
1.22 
1.14 
1.10 
1.10 
1.07 
-
NS* 
<0.001 
<0.001 
<0.001 
NS 
-
NS 
<0.01 
<0.001 
NS 
B6AF1 recipients were injected i.p. on days 0, 2, and 4 after transplantation. 
MST χ median survival time. 
"SD » standard deviation. 
ρ » level of significance (student's t-test) of the difference between the treated and the 
control group. 
NS * not significant. 
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The activity of the same anti SD preparations in enhancement is shown in 
table III. Treatment of B6AF1 recipients of a B10.D2 skin graft with 
2.5 yg of the anti H-2K preparation on days 0, 2, and 4 after transplantation 
prolongs graft survival with two days, which is a significant prolongation 
in comparison with the untreated control group. A dose of 4.0 yg increased 
the anti H-2K induced prolongation up to 4 days. Administration to the 
recipients of 0.1 ml of unfractionated B6AF1 anti B10.D2 serum prolonged 
graft survival to 18.9 days. In the specificity controls, treated with 
2.0 yg anti H-2D eluate, no enhancement was observed. In B6AF1 recipients 
of BIO.BR skin grafts, treatment on days 0, 2, and 4 with 2.0 ug of anti 
H-2D resulted in significant prolongation of graft survival from 14.7 to 
16.9 days. 
Administration of 0.25 ml of whole B6AF1 anti BIO.BR serum prolonged 
graft survival to 17.4 days. Treatment with 5.0 ug anti H-2K eluate as a 
specificity control did not induce enhancement in this model. 
DISCUSSION 
The results show that alloantibodies directed against H-2K and H-2D 
region determinants can cause destruction of mouse skin allografts. This 
is in agreement with the results of McKenzie and Henning (19) who used 
whole alloantisera in recombinant donor-recipient combinations in which 
only К or D region specificities of the donor were recognized by the 
antibodies. It is clear that acute antibody-mediated rejection is a 
function of SD antibodies. 
la antibodies, even in high doses, are not capable of evoking acute 
rejection of mouse skin allografts. This was shown by Jansen et al.(5), 
using antisera shorn of SD antibodies by absorption to donor strain RBC, 
and confirmed later by McKenzie and Henning (19), using recombinant 
mouse strain combinations. 
The different activities of anti SD and anti la antibodies in acute 
rejection can not be explained satisfactorily, since the presence of 
both SD and la antigens in skin tissue has been demonstrated by rejection 
of skin allografts in recombinant strain combinations (20). There are, 
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however, two possibilities to explain the difference in activity. The 
amount of la antigen in the graft can be too small to function as target 
for humoral attaque. Another explanation might be that the I region 
products causing cellular rejection of skin grafts are not identical 
with the serologically detectable la antigens. We consider the former 
explanation to be the more likely. 
The results presented in this paper indicate that anti H-2K and H-2D 
antibodies, apart from their destructive capacities, can play a role in 
the protection of mouse skin allografts. Since the anti H-2K and H-2D 
antibodies were isolated by elution of absorbed antibodies from red 
blood cells, one should be sure that no contaminating anti la antibodies 
are present. Especially the enhancing activity of the preparations could 
be easily caused by small amounts of anti la. Sources of contaminating 
anti la are antibodies absorbed to leukocytes that are left in the donor 
strain erythrocyte suspensions, and igG that is non-specifically absorbed 
onto the RBC. In our protocol, the erythrocyte suspensions were prepared 
by removal of the buffy coat in several centrifuge runs and passage 
through a cotton wool column. The purity of the suspensions was controlled 
by microscopic examination of stained smears of the cotton wool column 
eluates. Only suspensions containing less than 1 leukocyte per 105 
erythrocytes were used. Assuming that the absorption capacity of leukocytes 
exceeds that of erythrocytes by a factor 50 (21), at most 0.05% of the 
antibody activity in the anti SD eluates could be attributable to la 
antibodies. In the dose of 4.0 gg anti H-2K eluate we used, this would 
be 2 ng. Taking into account the 500-fold purification, this corresponds 
with 1 \ig of non-purified B6AF1 anti B10.D2 IgG2 with la specificity. 
Frcm the results of Jansen et al. (3) we know that this is a factor 19 
below the lowest enhancing dose of anti la IgG2 antibodies. 
It is highly unlikely that non-specific absorption of serum proteins 
including immunoglobulins from the alloantiserum to the RBC caused 
substantial contamination with la antibodies. Assuming that a dose of 
4 уд of anti H-2K IgG2 would merely consist of non-specifically absorbed 
IgG2, it would not suffice to account for the prolongation observed. 
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We have previously shown that at least 19 vg of B6AF1 anti B10.D2 IgG2 
Is required to obtain a comparable prolongation of graft survival (3). 
In B6AF1 recipients of BIO.BR skin grafts, significant enhancement could 
be induced by administration of anti H-2D eluate. Contamination of this 
preparation by anti la antibodies is unlikely, because, although there 
is a difference in the I-C subregion in this combination, no serologically 
detectable anti la antibodies are raised (14). Administration of whole 
B6AF1 anti В10.BR serum resulted in prolongation of graft survival 
comparable to that induced by administration of the anti H-2D eluate. 
This indicates that during the absorption and elution procedure no 
enhancing activity, attributable to putative la antibodies, is lost. 
Administration of whole alloantiserum in the B10.D2 •+ B6AF1 model does 
induce significantly longer prolongation of graft survival than does 
administration of the anti H-2K eluate. Absorption to and elution fron 
the donor strain RBC in this model accordingly results in loss of 
enhancing la antibodies. 
It is not clear at which level in the immune response the enhancing 
antibodies exert their blocking functions. la antigens are thought to 
play an important role in the recognition phase of the immune response 
(22). A model of collaboration between la recognizing Ly 1 T-helper 
cells and K, D recognizing Ly 2,3 T-killer cells was proposed (23), 
based primarily on in vitro results. This dichotomy concept was con­
firmed by the report of Nagy et al. (24), who found that Ly 1 T-cells 
specifically bound I-region products, and Ly 2,3 T-cells bound K-region 
products. It was suggested that enhancement by anti la antibodies is 
caused by inhibition of the recognition of I-region antigens from the 
graft by Ly 1 T-helper cells (25). This was in line with the reported 
гп vitro blocking of the mixed lymphocyte reaction by la antibodies 
(26), since this test can be regarded as an in vitro analogen of the in 
vivo recognition and proliferation phase. 
In vivo, anti la antisera induced increased opsonization of antigen 
reactive-cells in the liver (27). These antigen-reactive cells expressed 
the Ly 1 phenotype (28). 
Recent reports have shown, however, that K/D antigens on their own can 
give rise to an immune response. К as wel as D region differences can 
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lead to mixed lymphocyte culture stimulation. Induce a graft versus host 
reaction, give a positive result in the cell-mediated lymphocytotoxicity 
assay, and can lead to rejection of heart, tumor and skin grafts (20, 
8). It is conceivable that anti H-2K or H-2D antibodies can play a role 
in blocking of the recognition of К and D antigens, analogous to anti la 
blocking. Increased opsonization of antigen-reactive cells in mice 
treated with complexes of spleen cell antigen and anti H-2K.33 antibodies 
has recently been reported (2Θ), indicating that anti H-2K antibodies do 
have activity at this level. 
We conclude from our results that anti H-2K and H-2D antibodies have a 
weak but significant protective effect on graft survival in our model. 
The antibodies are probably working via the same mechanism as in enhancement 
by la antibodies, i.e. via the formation of Immune complexes consisting 
of anti H-2K or D and К or D antigens that are released from the graft. 
Free antigenic determinants present in these complexes bind to antigen 
reactive cells and subsequently inactivate these cells by means of Fc-
dependent mechanisms (29, 30). Opsonization of these cells is probably 
an important way by which this inactivation takes place (31). 
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Chapter 3 
IN VIVO ACTIVITY OF AN H-2 ALLOANTISERUM PURIFIED BY AFFINITY 
CHROMATOGRAPHY ON TRANSPLANTATION ANTIGENS 
Robert M.W. de Waal, Simon P.M. Lema, and Robert A.P. Koene 
From the Department of Pathology and the Department of Medicine, 
Division of Nephrology, University of Nijmegen, 
The Netherlands. 
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Transplantation antigens were isolated frao murine tissue by solubilization 
with NP-40 and purification on a lentil lectin-sepharose column. The 
glycoproteins eluted from the lectin column were coupled to CNBr-activated 
Sepharose to prepare a specific immunoadsorbent. Intact histocompatibility 
antigens were demonstrated on the carrier particles in a cytotoxic 
inhibition assay with specific antiserum and spleen lymphocytes. Adsorption 
and subsequent elution of alloantiserum directed against the coupled 
antigens yielded a 30-fold purified product. The presence of both active 
К and I region products on the column was demonstrated by the in vivo 
activities of the alloantibodies eluted from the coupled molecules. Both 
acute rejection, a function of H-2K antibodies, and passive enhancement, 
a function of la antibodies, could be induced by administration of the 
eluate to recipients of skin allografts. These in vivo results show that 
the adsorbent can be used for preparative purposes. 
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Passive enhancement of allografts in the mouse can be brought about by 
the Injection of antisera directed against I region products, and probably 
to a less extent by antisera against H-2K and D determinants (1). Enhancing 
la antisera can be raised in congenie mouse strain combinations that 
differ only in the I region of the H-2 complex. Alternatively, la antisera 
can be prepared from more complex antisera by absorptions with suspensions 
of red blood cells or platelets from appropriate mouse strains. By using 
this procedure contaminating antibodies against H-2K and D region antigens 
are removed (2,3). Although several authors have reported that with this 
method extensive prolongation of graft survival may be obtained in 
laboratory animals, it has the practical disadvantage that large amounts 
of cells of defined specificity are required for the absorptions. 
In additon, the absorption of sera with live cells is complicated by the 
possible shedding of membrane constituents, frequently in the form of 
immune complexes. Zola (4) found that 11.9% of membrane-associated 
radioactivity was released from lymphoblastoid cells during a 30-min. 
о 
absorption with antilymphocyte globulin at 4 C. Davies and ADcins (5) 
did not detect any immune complexes after RBC absorption, which suggests 
that the nature of absorbing cells is of importance in membrane shedding. 
Nevertheless, the possible release of immune complexes, which might be 
pathogenic, makes this approach less attractive for in vivo uses. A 
purification method, that gives rise to significantly less complexes 
makes use of specific immunoadsorbents prepared by the coupling of 
isolated antigen to a carrier particle. Several authors have used these 
columns for analytical purposes and have emphasized their reusability 
(6-8) . 
Depending on the nature of the coupled antigen, either the unbound 
fraction or the immunoglobulins eluted afterward may be usefull. To 
investigate whether products coded for by the К and I regions can be 
used for the production of immunadsorbents, a Sepharose column of CNBr-
coupled glycoproteins, including transplantation antigens, was made for 
preparative purposes. A mouse alloantiserum containing antibodies against 
I en К region antigens was absorbed to this affinity column. The H-2K 
antibodies present in this serum evoke acute rejection of skin allografts, 
while the la antibodies give enhancement. The presence of both activities 
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in the antibody eluted from the column would indicate that К as well as 
I region antigens had been effectively coupled. Therefore, the eluate 
was administered to recipients of skin allografts and tested for the 
presence of destructive and enhancing activity. 
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MATERIALS AND METHODS 
Animale 
BlO.D2/Sn (H-2 ) mice were originally obtained from The Jackson Laboratory, 
Bar Harbor, Maine. C57BL6/R1J (H-2 ) and A/Hej (Η-2*) mice were obtained 
fresa the Radiobiological Institute, Rijswijk, The Netherlands. B6AF1 
hybrids were produced in the laboratory by mating of C57BL6/Rij and 
A/HeJ mice. 
Antisera 
Alloantisera were prepared by injecting female mice at weekly intervals, 
i.p., with approximately 5 χ 10' allogeneic lymphoid cells in complete 
Freund's adjuvant. After five injections, most animals developed ascites 
and could be tapped every 1 to 2 weeks. The ascites fluid of several 
weeks was pooled and, before use, all antisera were heated at 56 С for 
45 minutes and sterilized by passage through a sterile 0.2-u filter. The 
cytotoxic titer of the ascites fluid was the same as the titer in the 
serum of the corresponding mice. Antilymphocyte serum was prepared by a 
s.c. injection of 5 χ 10 C57BL/6 lymphoid cells in complete Freund's 
adjuvant into a goat. 
This priming dose was followed by weekly i.v. boosters of the same 
number of C57BL/6 lymphoid cells. The animals were bled 1 week after the 
fourth immunization, the serum was heated at 56 С for 45 min, and absorbed 
once with C57BL/6 red blood cells (five volumes of serum/one volume of 
packed red blood cells). After absorption, this antilymphocyte serum was 
not toxic to the recipients if injected i.p. 
Lectin isolation and coupling 
Lens culinarie hemagglutinin (lentil lectin) was isolated from brown 
lentils according to the procedure described by Agrawal and Goldstein 
(9) for the isolation of concanavalin A. The lectin was purified by 
affinity chromatography to Sephadex G-150 (Pharmacia), using a 0.1 M 
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metfa/i-a-D-mannoside (Sigma) solution as eluent. Purified lectin was 
coupled to Sepharose-4B (Pharmacia) as described earlier for the coupling 
of IgG2 (10). 
Protein eatimation 
Total protein was measured according to the method of Lowry et al. (10a) 
with the following modification. To estimate the amount of protein 
solubilized in 0.5% NP-40, a standard curve was similarly determined 
with bovine serum albumin in 0.54 NP-40 as a standard, and, before 
reading the test, a precipitate which formed during the incubation with 
phenol reagent was removed by centrifugation. The amount of IgG2 was 
determined with the radial Immunodiffusion method of Mancini et al. 
(10b). One milliliter of agar gel was mixed at 56 С with 20 yl of 
specific goat antiserum, directed against murine IgG2 (Meloy). 
Cytotoxioity аввау 
Cytotoxic tests were performed using the trypan blue dye exlcusion 
method as described earlier (11). Rabbit semm was used as a source of 
ccmplement. Cytotoxic units are expressed as units per ml, i.e., cytotoxic 
titer Vml. Thus, in a typical assay, using 0.1 ml of sample, the 
concentration of cytotoxic units is given by the inverse titer times 10. 
Cytotoxic inhibition аввау 
Coupled antigen activity was determined in a two-stage inhibition test. 
A dilution series of antigen-Sepharose in Hanks' balanced salt solution 
(wherein undiluted = packed Sepharose) was preincubated at 37 С for 30 
min with a fixed alloantiserum dilution, which gave 90% cytolysis in the 
control experiment. One hundred microliters of antigen-Sepharose dilution 
were mixed with 100 μΐ of antiserum dilution. 
The Sepharose spheres were then carefully filtered away to prevent 
activation of the alternative pathway on the carbohydrate material and 
subsequent complement consumption (12). 
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One hundred microliters of the mixture were added to 100 μΐ of cell 
suspension (5 χ IO6 cells/ml) and 100 yl of rabbit complement. After an 
additional 30-min incubation at 37 С the test could be read. The inhibition 
titer is expressed as the dilution of antigen-Sepharose giving 50% 
inhibition of cell lysis. 
In vivo etudiee 
B10.D2 donor tail skin was grafted onto the right dorsal flank of a 
B6AF1 recipient. The graft was fixed with Nobecutane spray. A Band-aid 
was used as a cover. The donor and recipient mice were between 6 and 10 
weeks old. The Band-aid was removed on day 6 after transplantation and 
the fate of the grafts followed by daily macroscopic inspection. Rejection 
was considered to be complete when no viable epidermis was left. Median 
survival time and SEM were calculated according to the method of Litchfield 
(13). Enhancement of skin grafts was induced by i.p. injections of 0.25 
ml of alloantiserum at days 0, 2, and 4 after grafting (3). For acute 
antibody-mediated rejection (AAR), a previously described protocol was 
followed (14). Briefly, antilymphocyte serum-immunosuppressed recipients 
carrying established skin grafts received an i.v. injection of 0.25 ml 
of alloantiserum and 0.25 ml of rabbit complement at day 7 after 
transplantation. This resulted in destruction of the graft within 48 hr. 
RESULTS 
Antigen isolation and coupling 
The procedure for the isolation and coupling of transplantation antigens 
was originally set up in the C57BL/6 (H-2 ) •+ B10.D2 (H-2 ) model. A 1% 
w/v homogenate was prepared in cold phosphate-buffered saline (PBS), pH 
7.4, from C57BL/6 lymphoid tissue (spleen, thymus, and mesenteric lymph 
nodes) by treatment with a Potter-Elvehjem homogenizer. To this suspension, 
a 10% solution of MP-40 in PBS was added to a final concentration of 
0.5%. The extraction mixture was stirred at 4 С for 30 min and the 
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solubilized fraction isolated by centrifigation for 30 min at 48,000Ig. 
This fraction was subjected to lentil lectin affinity chromatography. 
The bound material was eluted with 0.1 M a-meí;%Z.-mannoside solution in 
0.5% NP-40-PBS. The yield of an elution run was determined by the Lowry 
procedure, and amounted 10 to 20 mg of (glyco)protein. To this solution, 
1 ml of CNBr-activated Sepharose-4B per mg of glycoprotein was added. 
Coupling was completed overnight under gentle stirring at 4 C, after 
which the gel was washed once and inactivated in 1 M ethanolamine (pH 
9.0) by gentle stirring for 4 hr. To remove NP-40 detergent, the Sepharose 
was carefully washed with cold PBS. Noncovalently bound proteins were 
removed by treatment with 1 M NaCl. In this way, 80% of the protein was 
coupled. 
Antigen activity, coupled to Sepharose, was measured in the cytotoxic 
inhibition assay. Figure 1A gives the inhibitory capacity of a preparation 
of C57BL/6 antigen-Sepharose. The inhibition of the cytotoxicity of a 
BIO.02 anti-C57BL/6 serum against C57BL/6 lymphocytes was specific, 
since the cytotoxicity in an irrelevant system (B6AF1 anti-BlO.D2 serum 
against B10.D2 lymphocytes) was unaffected by the immobilized antigen. 
Therefore, it seems that intact C57BL/6 antigen is present on the Sepharose 
spheres. 
To test both the absorption-elution qualities of an antigen-Sepharose 
column and the in vivo activities of the eluate, the same procedure was 
carried out using BIO.02 tissue as the starting material. In this way, 
the in vivo testing can be performed in the BIO.02 (H-2 ) -+ B6AF1 (H-
2 ) model, in which the conditions for both acute antibody-mediated 
rejection and immunological enhancement of skin grafts are well defined 
(3). 
The isolation and coupling procedure was applied to material derived 
from 150 BIO.02 spleens. Antigen activity, coupled to the Sepharose 
carrier was tested in the cytotoxic inhibition assay (fig. IB). Again, 
antigen activity was detectable on the Sepharose. With this preparation 
absorption and elution experiments were performed with a total volume of 
BIO.02 immunoadsorbent of 10 ml. 
0/ecell lysis 
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Fig. 1A. Inhibition of the cytotoxicity of B10.D2 anti-C57Bl/6 serum 
(1:6 dilution) against C57B1/6 spleen cells (0) by immobilized 
C57B1/6 glycoproteins. The cytotoxicity of B6AF1 anti-B10.D2 
serum (1:32 diliution) against BIO.02 spleen cells (A) was not 
inhibited. 
IB. Inhibition of the cytotoxicity of B6AF1 anti-BlO.D2 serum 
(dilution 1:64) against BIO.02 spleen cells (Δ) by Immobilized 
В10.02 glycoproteins. 
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Adaorption of B6AF1 anti-BIO.D2 serum and elution from B10.D2 antigen-
Sepharoee 
Five milliliters of B6AF1 anti-BlO.D2 senm were applied to the antigen 
column. The column was washed with PBS at a flow rate of 300 ml/hr to 
remove unbound material. Adsorbed proteins were eluted with 0.05 M 
citrate buffer at pH 2.6, containing 1 M NaCl. The eluate was neutralized 
inmediately with TrisHCL to avoid loss of biological activity. The 
column was reequilibrated with PBS. Eluates from two subsequent runs 
were mixed, concentrated by ultrafiltration to their original volume of 
10 ml, dialysed against PBS, and sterilized by filtration through a 0.2-μ 
sterile membrane filter. 
In vitro testing of the eluate 
The amount of IgG2 in the eluate was determined by radial immunodiffusion. 
The IgG2 subclass is for the greater part responsible for the in vivo 
enhancing and destructive activities of the B6AF1 anti-B10.D2 serum 
(15). The activity of the eluate can therefore be expressed per ug of 
IgG2: this specific activity must increase during a successful purification 
procedure. The eluate contained 70 yg of IgG2 per ml. In a cytotoxic 
test against B10.D2 spleen lymphocytes, the cytolytic capacity of the 
eluate was determined. The result in Figure 2 shows that the cytotoxicity 
of the unfractionated B6AF1 anti-B10.D2 serum is almost completely 
preserved in the eluate. Specific activity, however, expressed as cytotoxic 
units per ug of IgG2, is raised by a factor of 30 (Table 1). Thus, 
absorption and elution of the B6AF1 alleantiserum on the B10.D2 spleen 
antigen column resulted in a purified antibody preparation, indicating 
again that specific antigen activity is preserved during the isolation 
and coupling procedure. 
In vivo activity of the eluate 
The unfractionated B6AF1 anti-Bl0.D2 serum is directed against H-2K and 
la determinants. It has two distinct activities in the B10.D2 ->• B6AF1 
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Fig. 2. Cytotoxicity against B10.D2 spleen cells of the antigen column 
eluate (A) comoared to whole B6AF1 anti-B10.D2 serum (0). 
TABLE I 
Spécifia activity of the antibody preparation 
Concentration of Cytotoxic Specific 
p
 IgG2 (pg/ml) units per ml activity 
B6AF1 anti-BlO.D2 serum 4000 5120 1.28 
Antigen column eluate 70 2560 36.57 
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transpLantation model. In the enhancement protocol, graft survival is 
prolonged freo 11.2 to 18.9 days. The same antiserum induces graft 
destruction if injected along with rabbit complement at day 7 after 
transplantation. Antibodies directed against I region differences hace 
enhancing activity, while AAR cannot be evoked, not even with high 
dosages of la antibodies (3). On the other hand, the H-2K antibodies can 
cause AAR (unpublished observation), but their role in enhancement is 
not yet clear. So far, only marginal prolongation of graft survival has 
been obtained (1). Since both la and H-2K antigens have been subjected 
to the coupling procedure, we expected both activities to be present in 
the eluate. 
Table 2 shows the activity of this preparation in the enhancement protocol. 
The enhancing activity is preserved in the column eluate. As in the 
cytotoxic test, the activity is somewhat less than that produced by the 
same volume of unfractionated alloantiserum, but the MST is still 
significantly prolonged as compared to that found with normal B6AF1 
serum. Table 3 shows the activity of the eluate in the AAR protocol. 
Acute graft destruction results after the injection of the eluted anti-
body preparation together with rabbit complement. Here also, a higher 
dose is required to obtain the same effect as with whole antiserum. 
DISCUSSION 
The results show that a specific immunoadsorbent can be prepared by 
coupling NP-40-extracted and lectin-purified antigen to CNBr-activated 
Sepharose. The in vivo and in vitro properties of the absorbed antiserum 
are preserved in the eluted antibody population. The high purification 
factor, as demonstrated by the rise in specific activity after elution, 
is an indication that nonspecific binding of proteins to the immunoadsorbent 
is relatively low and that the activities of the eluate are therefore 
attributable to antibodies specifically bound to coupled antigen. In the 
literature eluates have been reported with 10 to 15 times increased 
specific activity in vitro (8,16). 
The preservation of enhancing as well as AAR activity indicates that 
TABLE Π 
Enhancing effect of the antibody preparation on B10.D2 ekin grafia in B6AP1 recipients 
„ a „_ . ,.Ъ MSTC + SEM No. Treatment ,, — , (days) 
10 3 χ 0.25 ml of normal B6AF1 serum 11.2 +_ 1.0 
θ 3 χ 0.25 ml of column eluate 16.2 + 1.1 
10 3 χ 0.25 ml of B6AF1 antl-Bl0.D2 serum 18.0 +1.1 
dumber of recipients. 
Injection at days 0, 2, and 4 after grafting. 
с 
MST, median survival time. 
TABLE III 
Destructive capacity of the antibody preparation on B10.D2 akin grafts in B6AF1 recipients 
a „_ ,_ ^b Acute antibody No. Treatment ,. . . . .: 
mediated rejection 
10 0.25 ml of normal B6AF1 serum 
10 0.25 ml of B6AF1 anti-B10.D2 serum +C 
7 0.5 ml of column eluate + 
Number of recipients. 
Received injection of alloantiserum and 0.25 ml of rabbit complement at day 7 after grafting. 
с 
+, rejection of the graft within 48 to 72 hr after injection. 
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both la and H-2K antigens are effectively coupled in this procedure. It 
should therefore be possible to prepare specific immunoadsorbents from 
isolated H-2K or D antigens with which polyspecific antisera can be 
absorbed to yield pure anti-la sera in such amounts, that they can be 
used in vivo. The main obstacle to this approach remains the source of 
pure antigen. Studies on the separation and purification of H-2K and D 
antigen via affinity chromatography on coupled antibodies have been 
carried out (17). It is possible that H-2K or D antigen will first have 
to be purified in such a way, since direct isolation from tissues like 
liver, which lacks la antigens, meets with serious difficulties (18, 
19). Although the shedding of material from immunoadsorbents is much 
less than from viable or fixed cells, it is probably not completely 
absent (4). Better coupling methods will have to be designed to minimize 
this undesired effect. If these problems can be solved, the method may 
be very useful for the purification of defined antibodies from complex 
antisera. 
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Chapter 4 
PASSIVE ENHANCEMENT OF MOUSE SKIN ALLOGRAFTS BY 
ALLOANTIBODIES IS Fc DEPENDENT 
P.J.A. Capel, W.P.M. Tamboer, R.M.W, de Waal, J.L.J. Jansen and R.A.P. 
Koene 
From the Departments of Medicine, Division of Nephrology, and Pathology, 
University of Nijmegen, Sint Radboud Ziekenhuis, Nijmegen, 
The Netherlands 
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Chapter 4 was published in the Journal of Immunology 1979 
Vol. 122, No. 2, page 421 
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The capacity of F(ab')2 fragments of alloantibodies to enhance mouse 
allografts was studied in B6AF1 recipients of B10.D2 skin grafts. 
F(ab')2 obtained by digestion of B6AF1 anti BIO.02 antibodies was 
purified by means of affinity chromatography, with anti-subclass antisera 
and protein A. The degree of contaminating IgG was less than 0.02%. 
Administration of F(ab1)2 with an antigen-binding capacity similar to 
the IgG from which it originated, inhibited acute antibody-mediated 
graft rejection but was unable to induce enhancement. Even a dose that 
was 130 times the molar amount of the minimal enhancing dose of undigested 
IgG2 was ineffective. We conclude, therefore, that passive enhancement 
of mouse skin allografts by alloantibodies requires the Fc part. 
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Administxation of alloantibodies to recipients of allografts can result 
in the enhancement of these grafts. The mechanism of immunologic enhancement 
is not fully understood and one important question is whether the Fc 
part of the alloantibodies is necessary to induce this phenomenon. 
F(ab1)2 fragments lacle cytotoxic activity and, if inducing enhancement, 
the use of F(ab')2 would overcome the problem of antibody-mediated 
rejection that can occur after administration of alloantibodies. The 
role of F(ab')2 has not only been studied in graft enhancement models, 
but also in systems where administration of antibodies induces specific 
suppression of antibody formation, a phenomenon that is probably related 
to enhancement. (Fab1)2 could suppress the antibody response to sheep 
red blood cells in vivo (1,2) and in vitro (3,4), although IgG was much 
more suppressive than F (ab')2. In another study F(ab')2 was unable to 
suppress an in vitro response (5). Furthermore, F(ab')2 was unable to 
terminate an established immune response in contrast to IgG (6). In the 
mixed leukocyte reaction F(ab')2 fragments of histocompatibility anti-
bodies were orginally shown to act inhibitory (7-9), but Nielsen et al. 
(10), using a more purified F(ab')2 preparation, found this inhibition 
to be Fc dependent. F(ab')2 fragments of alloantibodies induced enhancement 
of allografts of normal tissues (11-6) and also of tumors (17). when 
F(ab')2 was compared with IgG it was always found to be less active and 
this difference in activity suggested the presence of two mechanisms, 
one being Fc dependent and the other Fc independent. Crucial in these 
types of experiments is the purity of the F(ab')2 preparations used. 
Contaminating IgG might be responsible for some of the results obtained 
and might go undetected due to the relative insensitivity of the test 
systems used for IgG determinations. In the current study we have tried 
to exclude the role of contaminating IgG by using highly purified F(ab,)2 
fragments of alloantibodies. With such preparations we were unable to 
induce passive enhancement of mouse skin allografts in a model in which 
antibodies consisting of intact IgG induce significant prolongation of 
graft survival (18). 
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MATERIALS AND METHODS 
Animale 
Inbred strains of B10.D2 and BIO.BR mice were originally obtained fremi 
Jackson Laboratory (Bar Harbor, Maine). B6AF1 hybrids were raised by 
mating of C57BL6/RÌJ and A/HeJ mice obtained from the Radiobiological 
Institute, Rijswijk, The Netherlands. 
Antisera 
B6AF1 anti B10.D2 ascites fluid was obtained by weekly i.p. injections 
of a suspension of 5 χ 107 B10.D2 lymphocytes in complete Freund's 
adjuvant (Difco, Detroit, Mich.). After 5 to 6 weeks the animals developed 
ascites, which was tapped weekly. The lymphocytotoxlc activity of the 
ascites fluid was similar to the activity present in serum. The ascites 
fluid was sterilized by passing through a series of membrane filters 
(Schleicher and Schüll, Dassel, W. Germany) with decreasing pore sizes 
ranging from θ μ to 0.2 μ. The preparation contained antibodies against 
antigens coded by the H-2K and I-regions of the mouse H-2 complex and 
against sane minor non H-2 antigens (H-9). Anti-mouse F(ab')2 antibodies 
were raised in rabbits by intramuscular (i.m.) injection of 100 ug 
F(ab')2 fragments of mouse IgG in complete Freund's adjuvant. After 
three weeks, this was followed by weekly injections of 100 ug F(ab,)2 in 
incomplete Freund's adjuvant. Anti-lymphocyte serum (ALS) was raised in 
goats by i.m. injections of S χ 10e C57BL6/RÌJ lymphocytes suspended in 
complete Freund's adjuvant followed by two weekly i.v. injections of 
5 χ 10e C57BL6 lymphocytes in saline. Anti-mouse erythrocyte antibodies 
were removed from the ALS by absorption with C57BL6 erythrocytes. Goat 
antisera against mouse IgG and subclasses thereof, and against IgA and 
IgM, were obtained from Meloy Labs, (Springfield, Va). FITC conjugated 
horse anti-rabbit immunoglobulin serum was obtained from the Central 
Laboratory of the Red Cross Blood-transfusion Serive Amsterdam, The 
Netherlands. All antisera used in vivo were heat-inactivated at 56 С 
for 30 min. 
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Antibody columna 
Sepharose 4B (Pharmacia, Uppsala, Sweden) was activated with 50 mg 
CNBr/ml (Koch Light, Colnbrook, U.K.) packed Sepharose at pH 10 according 
to Cuatrecasas (19). A 50% saturated ammonium sulphate precipitate of the 
various antisera was coupled after dialysis against phosphate-buffered 
saline (PBS) in a concentration of 5 mg/ml packed Sepharose overnight at 
4 C. The degree of coupling was determined spectrophotometrically and 
ranged from 90 to 95%. The Sepharose was inactivated with 5 volumes 1 И 
ethanolamine (Merck, Darmstadt, W. Germany), pH 9.0, for 3 hr at room 
temperature and washed extensively with PBS. 
Isolation of IgG 
Antibodies from B6AF1 anti BIO.02 ascites fluid or normal B6AF1 serum 
were twice precipitated by addition of equal volumes saturated ammonium 
sulphate. After dialysis against 0.1 M Tris HCl buffer, pH Θ.0, containing 
0.2 M NaCl, the immunoglobulins were chrcmatographed on BioGel A 0.5 M, 
200-400 mesh (Biorad, Richmond, Calif.). Instead of gel filtration 
Sepharose coupled Protein A (Pharmacia, Uppsala, Sweden) also was applied. 
IgG was eluted from this column with 0.1 M Na-citrate buffer, pH 2.8, 
containing 1 M NaCl. The eluate was immediately neutralized and dialyzed 
against PBS. Parts of these IgG preparations were used to prepare an 
IgG2 fraction by affinity chromatography as described earlier (18). 
Isolation of F (ab') 2 
After dialysis against 0.1 M Na-acetate, pH 4.0, IgG (20 mg/ml) obtained 
from B6AF1 anti B10.D2 ascites fluid or normal B6AF1 serum was digested 
with 2% (w/w) pepsin (Boehringer, Mannheim, M. Germany) for 18 hr at 37 с 
After adjustment of the pH to pH 8.0, the digest was chromatographed on 
BioGel A 0.5 M in order to remove pepsin and separate undigested IgG 
frem F(ab')2. The pooled F(ab')2 fractions always contained undigested 
IgG as determined by Polyacrylamide gel electrophoresis and by gel 
diffusion by using anti-mouse IgG subclass antisera that are only reactive 
with derminants present on the Fc part. F(ab')2 was further purified 
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either by rechromatography on BioGel A 0.5 M or by affinity chrcjmatography 
with antibody columns or combinations of Sepharose-proteln A and antibody 
columns. These columns were regenerated with one column volume of 0.1 M 
Na-citrate, pH 2.8, containing 1.0 M NaCl followed by extensive washing 
with PBS. To remove the final contaminants the preparations were batch-
wise incubated with the antibody-coated Sepharose for 16 hr at room 
temperature. 
Cytotoxicity assay 
The in vitro cytotoxic activity of alloantisera was determined by trypan 
blue exclusion with B10.D2 or BIO.BR spleen cells freed of erythrocytes 
by treatment with NH4CL. One-tenth milliliter of a cell suspension (5 χ 
IO6/ml) was incubated with 0.1 ml of a dilution series of alloantibody 
in Hanks' balanced salt solution and 0.1 ml of a dilution series of 
alloantibody in Hanks' balanced salt solution and 0.1 ml diluted (1:4) 
rabbit serum as complément (С) source for 30 min at 37 C. The rabbit 
sera were preselected, and only those sera that lysed 10% or less of the 
mouse lymphocytes in the absence of alloantibody were used. 
Indirect imnunofluoveecence 
One-tenth milliliter of BIO.02 or BIO.BR thymocytes (5 χ 10б cells/ml) 
was incubated with 0.1 ml of a dilution series of B6AF1 anti B10.D2 
ascites fluid or F(ab')2 fragments thereof (5 mg F(ab')2/ml) for 30 min 
at room temperature. After three washings with PBS the cells were incubated 
with 0.1 ml of an appropriate dilution of rabbit anti-mouse F(ab')2 
antiserum for 30 min at room temperature followed by three washings and 
a similar incubation with FITClabeled horse anti-rabbit immunoglobulin 
antiserum. After three washings the cells were scored for 
immunofluorescence. The whole procedure was carried out in the presence 
of 0.054 sodium azide to prevent capping. 
akin grafting 
Transplantation of BIO.02 tail skin onto B6AF1 recipients was carried 
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out as earlier described (18). 
Enhancement of allografts 
If nor mentioned otherwise, enhancement was induced in B6AF1 recipients 
of B10.D2 skin grafts by i.p. injections of 0.25 ml alloantiserum or a 
F(ab')2 preparation on days 0, 2, and 4 after grafting. 
Acute antibody-mediated graft rejection (AAR) 
Acute rejection of well established grafts am immunosuppressed recipients 
could be achieved by i.v. injection of alloantibodies together with 0.25 
ml rabbit С at day 10 after grafting (20). The recipients were 
immunosuppressed by i.p. injection of 0.25 ml ALS on days 0, 2, and 4 
after grafting. The rabbit serum used as С source was preselected and 
had no cytotoxic effect on mouse lymphocytes as measured in the in vitro 
test. 
RESULTS 
Purification of F (ab') 2 
Several steps were necessary to purify the F(ab')2 fragments of B6AF1 
anti B10.D2 IgG. Undigested IgG was separated from F(ab')2 by gel 
filtration on BioGel A 0.5 M. The F(ab')2-containing fractions were 
pooled, concentrated and rechromatographed. Analysis of this F(ab')2 
preparation on Polyacrylamide gel electrophoresis showed a 7S band, and 
in gel diffusion with anti-mouse subclass antisera undigested IgG could 
also be detected. Therefore, anti-IgG1 and IgG2 antibody columns were 
applied twice to remove contaminating IgG. In such F(Ab')2 preparations 
small amounts of IgG and IgA could still be detected and therefore an 
isolation procedure was devised in which F{ah')2 was passed three times 
through a protein-Α-column and four different antibody columns (IgGl, 
IgG2, IgM, IgA). After the final purification step F(ab,)2 was concentrated 
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to 15 mg protein/ml and analyzed for contaminating Ig by radial immuno-
diffusion. No contaminating IgGl, IgG2, IgA or IgM could be detected 
anymore. With a standard of mouse Immunoglobulins the lower limit of 
detection of the radial immunodiffusion technique was determined. The 
results of these isolation procedures are given in Table I. Analysis of 
the purest F(ab')2 preparation by Polyacrylamide gel electrophoresis 
resulted in a single band that corresponded to a m.w. of about 115,000 
dalton and that had a sedimentation coefficient of S 20 =» 4.91 + 0.03 
w — 
as determined by analytical ultracentrifugation. Unless noted, this 
F(ab')2 preparation was used in all experiments. 
Jn vitro activity of F (ab') 2 
In order to determine whether F(ab')2 had retained antigen-binding 
activity during the digestion or purification procedures a dilution 
series of F(ab')2 (5 mg/ml) was tested by indirect immunofluorescence 
and compared with the binding of B6AF1 anti B10.D2 ascites fluid, which 
contained 4 mg IgG/ml. Because anti-IgG antisera react predominantly 
with the Fc part of the IgG, rabbit anti-mouse F(ab')2 antiserum was 
used to obtain comparable results. The titers were 1:256 for F(ab')2 and 
1:128 for the ascites fluid. Thus, F(ab')2 had similar antigen-binding 
activity as the original IgG, when compared on a molar basis. The titer 
with control BIO.BR thymocytes was 1:2 both for F(ab,)2 and IgG. The in 
Vitro activity of F(ab')2 was also tested by the inhibition of the 
cytotoxic activity of IgG. Dilutions of B6AF1 anti B10.D2 and B6AF1 anti 
BIO.BR ascites fluid giving 90% lysis, respectively, of B10.D2 and 
BIO.BR spleen cells were used in the cytotoxicity assay after preincubation 
of the cells with a dilution series of F(ab')2 (5 mg/ml). The results 
given in Figure I show that F(ab')2 specifically inhibits the cytotoxic 
activity of B6AF1 anti B10.D2 alloantibody. 
Inhibition of AAR of F(ab')2 
Although antigen binding by F(ab')2 and blocking of cytotoxicity was 
shown in vitro, it is not self-evident that this also occurs in vivo. 
TABLE I 
Purification of F(ab')2 after pepsin digestion 
Treatment No. of 
Treatments 
Percentage of Con­
taminating Ig 
1. Bio-Gel A 0.5 M 7S Ig 
2. Bio-Gel A 0.5 M 
Anti-IgGl-Sepharoae 
Q 
Anti-IgG2 -Sepharose 
IgA 3% 
IgGl 0.25% 
IgG2 0.2% 
3. Bio-Gel A 0.5 M 
Protein A-Sepharose 
Antl-IgG1-Sepharose 
Anti-IgG2-Sepharose 
Anti-IgA-Sepharose 
Anti-IgM-Sepharose 
IgA < 0.03% 
IgM < 0.05% 
IgGl < 0.02% 
IgG2 < 0.02% 
a Determined by radial immunodiffusion with the use of F(ab')2 
preparations with a concentration of 15 mg protein/ml. 
b Determined by Polyacrylamide gel electrophoresis. 
с Antibody column contained anti-IgG2a as well as anti-IgG2b. 
% Lysis 
dilution of Fabj 
Fig. 1. Inhibition of cytotoxicity by B6AF1 anti-B10.D2 F(ah,)2. 
The inhibitory capacity of a dilution series of F(ab')2 
(5 mg/ml) was tested on a 1/150 dilution (Δ Δ) and 
a 1/200 dilution (0 0) of B6AF1 anti-Bl0.D2 ascites 
fluid with B10.D2 spleen cells, or on a 1/6 dilution 
( Π — О ) and a 1/8 dilution (+ +) of B6AF1 anti-
B10.BR ascites fluid with BIO.BR spleen cells (specificity-
control) . 
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The half-life of F(ab')2 гп vivo is decreased in comparison with IgG 
(21). Whether F(ab')2 could sufficiently interact with the graft was 
tested by using the inhibition of AAR. Because AAR in mice is C-
dependent and in this process the entire classical pathway is involved 
(22), F (ab')2 should be ineffective to induce AAR. This was tested by 
the administration of various amounts of F(ab')2, ranging from 50 to 
1500 yg, together with 0.25 ml rabbit C, to immunosuppressed B6AF1 
recipients of B10.D2 skin on day 10 after grafting. In none of the cases 
signs of rejection were observed whereas administration of IgG in this 
way always resulted in the acute rejection of the graft within 24 to 48 
hr. The ability of F(ab')2 to inhibit this IgGinduced rejection was 
tested by the administration of 1 mg Τ{ah')2, 2 hr before the injection 
of 0.2 ml B6AF1 anti-BlO.D2 antibodies and 0.25 ml rabbit С As controls, 
either 0.2 ml alloantibody or 1 mg F(ab)2 was given together with rabbit 
С The results given in Tabel II show that F(ab')2 inhibited the AAR 
completely, which proves that F(ab')2 can interact sufficiently long 
with the graft antigens to prevent the destructive effects of allo­
antibody and C. 
Enhancement of skin allografts by F(ab')2 
The ability of F(ab')2 to induce passive enhancement of allografts was 
tested with two F(ab')2 preparations. One purified by rechromatography 
on Bio-Gel A 0.5 M and the second by gel filtration followed by extensive 
affinity chromatography. Both F(ab')2 preparations were noncytotoxic for 
B10.D2 lymphocytes and did not induce AAR. F(ab,)2 purified by gel 
filtration was still contaminated with undigested IgG and F(ab'2) obtained 
after affinity chromatography contained less than 0.024 IgG (Table I). 
Three hundred-seventy-five micrograms contaminated F(ab')2, 500 ug pure 
F (ab')2 and 350 vq F(ab')2 from normal B6AF1 IgG were administered to 
three groups of B6AF1 mice at days 0, 2, and 4 after grafting of B10.D2 
skin. Table III shows that pure B6AF1 anti-B10.D2 F(ab,)2 did not enhance 
the graft whereas a significant increase in graft survival was obtained 
with F(ab')2 containing some contaminating IgG. The inability of F(ab,)2 
to induce enhancement might be due to the decreased half-life of F(ab,)2 
TABLE II 
Inhibition of acute antibody-mediated graft rejeotion (AAR) by F(ab')2 
__ ^_ ^ No. Re- . . _ M.S.T. + S.D. 
Treatment -ч«*«,-*- ^ 1 1 ·, 
c i p i e n t s ¿¡зуд 
None θ - 2Θ.0 + 1.3 
Alloantibody + complement 5 + 
F(ab')2 (1 mg) + alloantibody + 
complement 8 - 27.0 +_ 1.1 
P(ab,)2 (1 mg) + complement 5 - 27.0 + 1.0 
AAR Is evoked by administration of 0.2 ml B6AF1 antl-B10.D2 serum together 
with 0.25 ml rabbit complement to imsiunosuppressed B6AF1 recipients on day 
10, after grafting of BIO.02 skin. 
TABLE III 
Faseive enhancement by F(ab')2 in B6AF1 recipients of B10.D2 ekin grafts 
Treatment 
None 
Normal B6AF1 F{ab,)2, 500 ug 
Ρ(ab·)2 (contaminated with IgG) 
375 wg 
F(ab,)2d (IgG < 0.02%), 500 wg 
No. Re­
cipients 
10 
10 
θ 
10 
M •S.T. + S.D. 
11.2 + 1.0 
11.8 + 2.0 
14.0 + 1.2 
11.0 + 1.1 
ь 
Ρ 
N.S.C 
<0.01 
N.S. 
Dose given on days 0, 2, and 4 after grafting. 
Level of significance (Student's t-test). 
N.S.« not significant. 
Flab')2 fragments of B6AF1 anti B10.D2 IgG. 
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гп vivo. То exclude this possibility multiple daily injections were 
given. The experimental protocols and the results are given in Table IV. 
The administration of a total dose of 2500 yg F(ab')2 in this way did 
not induce enhancement. To compare the enhancing activity of XgG2 and 
F(ab')2 various amounts of B6AF1 anti-B10.O2 IgG2 and F(ab')2, ranging 
from 9 to 1875 ug, were given on days 0, 2, and 4 to B6AF1 recipients of 
a BIO.02 skin graft. The results given in Figure 2 show that three 
injections of 9 ug IgG2 already induced a significant enhancement, 
whereas F(ab')2 lacked effect in all doses tested. 
DISCUSSION 
Administration of F(ab')2 fragments of alloantibodies to recipients of 
mouse skin allografts did not result in the enhancement of the graft. 
This inability of F(ab')2 to induce enhancement is either due to a 
decreased capacity to bind antigen in vivo or to the absence of the Fc 
fragment. When tested in immunofluorescence F(ab')2 was as active as the 
IgG from which it was derived. In this test anti F(ab')2 antibodies were 
used in order to compare results obtained with F(ab')2 and IgG preparations. 
F(ab')2 was also able to inhibit specifically the in vitro cytotoxicity 
of alloantibodies. Thus, the antigen-binding capacity of T(ah,)2, as 
measured in vitro, was not affected by the digestion or purification 
procedures. The effective binding to antigen in vivo, however, might be 
reduced by the decreased half-life of F(ab')2 (21). We tried to exclude 
this possibility by multiple daily injections of F(ab')2. Evidence that 
F(ab')2 could sufficiently interact with the graft is given by the 
inhibition of the acute antibody-mediated rejection. A single injection 
of 1 mg F(ab')2 completely inhibited the acute rejection by alloantibody. 
When comparing the enhancing activity of IgG2 and F(ab')2 we found that 
a total of 27 ug IgG2 already induced a significant enhancement, whereas 
a total of 2500 yg F(ab')2 had no effect. Compared on a molar base, IgG2 
is at least 130 times more efficient than F(ab')2. From these findings 
we conclude that F (ab')2 fragments of alloantibodies are unable to 
induce enhancement of allografts. This is in contrast to findings reported 
TABLE IV 
Passive enhancement by multiple injections of F(ab')2 in B6AF1 recipients 
of B10.D2 skingrafts 
Treatment 
1 χ 250 ug on day 4 
No. Re- M.S.T. + S.D. 
cipients daus 
Normal B6AF1 F(ab')2 
350 yg on daya 0, 2, and 4 10 11.θ + 2.0 
B6AF1 anti-Bl0.D2 F(ab')2 
3 χ 50 ug on days 0, 1, 2, and 3 10 11.2 + 1.0 
B6AF1 anti-B10.D2 F(ab,)2 
3 χ 250 yg on day 0 
2 χ 250 yg on day3 1, 2, and 3 7 11.5+1.2 
500 1000 
pg protein injected 
Fig. 2. Passive enhancement of B10.D2 skin grafts in B6AF1 recipients 
by administration of B6AF1 anti-B10.D2 IgG2 (+ +) or 
Fiab%)2 fragments thereof (i A) on days 0, 2, and 4 after 
grafting. 
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by other authors (11-17). This might be due to differences in the purity 
of the F(ab')2 preparations used. In some studies enhancement was obtained 
by using preparations from which undigested IgG was not separated from 
F(ab')2 (11-14). In other reports F(ab')2 was separated from undigested 
IgG on the basis of differences in m.w. (15-17). In our hands such 
procedures resulted in an enrichment of F(ab')2 preparations but not in 
a total removal of undigested IgG. We could demonstrate that the amount 
of contaminating IgG remaining after rechromatography on Bio-Gel A 0.5 M 
was sufficient to induce significant enhancement. This enhancing activity 
could be removed by repeated affinity chromatography with protein A and 
anti-subclass antisera, which all react with the Fc part of immunoglobulins. 
The absence of cytotoxic activity is not a reliable measure of the 
degree of undigested IgG in a F(ab1)2 preparation because of the inhibition 
of this cytotoxicity by F(ab')2 itself. We therefore used the reaction 
with anti-subclass antisera as a criterion for purity. The inability of 
F(ab')2 to induce enhancement shows that simple masking of antigenic 
determinants, although this occurs as is shown by the inhibition of AAR 
by F(ab')2, does not adequately explain the phenomenon of immunologic 
enhancement. A Fc-dependent mechanism should be at work. 
A possible mechanism of enhancement could be that the administered 
antibodies form immune complexes with cellbound (passenger cells) or 
soluble antigena released from the graft. These immune complexes could 
then inactivate antigen reactive cells upon binding to these cells and 
the inactivation takes place by virtue of the Fc part. That this process 
indeed might occur is suggested by the opsonization of antigen reactive 
cells in rats bearing passively enhanced renal allografts (23,24). The 
inactivation mechanism does not necessarily occur via opsonization 
alone, but antibody-mediated cell-dependent cytotoxicity or С activation 
could also be involved. Apart from these theoretical considerations the 
results of our study suggest that the outlook for the use of F(ab')2 
fragments to induce specific immunosuppression in clinical transplantation 
is not favorable. 
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CHAPTER 5 
PASSIVE ENHANCEMENT OP MOUSE TUMOR ALLOGRAFTS 
BY ALLOANTIBODIES IS Fc-DEPENDENT 
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Enhancement of growth of a B10.D2 flbrosarccna in B6AF1 recipients could 
be induced by administration of B6AF1 anti B10.D2 lymphocyte serum. The 
role of the Fc part in this phenomenon was studied by treatment of the 
B6AF1 recipients with F(ab')2 fragments of enhancing alloantibodies. A 
highly purified F(ab1)2 preparation was used to exclude any effects of 
undigested IgG. Administration of F(ab*)2 did not lead to enhancement of 
the tumor allografts, not even when given in a dose that was 22 times 
the molar amount of the lowest enhancing dose of undigested IgG. We 
therefore conclude that passive enhancement of mouse tumor allografts by 
alloantibodies is Fc dependent. 
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Tumor allografts show enhanced growth in several animal models if the 
tumor-bearing recipients are injected with alloantisera against donor 
transplantation antigens. This phenomenon is caused by a specific 
antibody mediated suppression of the cellular immune response to the 
graft. Similarly, these antibodies can specifically inhibit cellular 
immune responses in vitro. Studies of the role of the Fc part of the 
antibody molecule in these reactions by using F(ab')2 fragments suggested 
that the inhibition was Fc-independent, both in vitro (13) and in vivo 
(4-β), including the inhibition of the cellular immune response against 
tumor allografts (9-11). These findings, however, are unexpected in the 
light of other studies demonstrating that the Fc part is required for 
feedback suppression of the humoral response by antibody in vitro (12, 
13) and in VÌVO (14-16). Contaminating IgG in the Ρ(β^)2 preparations 
might account for the suppressive activity on the cellular immune response. 
In earlier studies we have found that minimal amounts of IgG can induce 
specific immunosuppression leading to enhancement of mouse skin allografts 
(17). The purity of the F(ab')2 preparations used should therefore be 
well defined to exclude that intact IgG is still present in a suppressive 
dose. We now report the effect of highly purified F(ab,)2 fragments of 
alloantibodies on tumor allograft survival, showing that even with high 
doses of F(ab')2 no enhancement can be induced in a model in which 
intact alloantibodies cause progressive timor growth. 
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MATERIALS EN METHODS 
Animala 
Inhred strains of B10.D2/new SN(H-2 ), A/HeJ(H-2a) and BIO.BR (H-2k) 
mice were originally obtained from the Jackson Laboratory (Bar Harbor, 
Maine, U.S.A.). 
C57B16/RÌJ (H-2 ) mice were obtained from the Radiobiological Institute 
TNO, Rijswijk, The Netherlands. (C57B16RÌJ χ A/HeJ)Fl (-B6AF1) hybrids 
(H-2 ) were raised by brother-sister matings. 
Antisera 
B6AF1 anti B10.D2 and B6AF1 anti BIO.BR ascites fluids were raised as 
described (IS). 
Preparation of F(ab')2 fragmenta 
IgG was prepared from B6AF1 anti BIO.02 ascites fluid by adsorption on 
protein A, coupled to Sepharose 4B (Pharmacia, Uppsala, Sweden). 
Elution was performed using 0.1 M Na-citrate buffer, PH 2.Θ, containing 
1 M NaCl. The eluate was immediately neutralized and dialyzed against 
PBS. F(ab')2 fragments of B6AF1 anti B10.D2 IgG were prepared, purified 
and assessed for antigen binding activity according to the procedure 
described in detail by Capei et al (19). 
Briefly, a pepsin digest of IgG was purified by affinity chromatography 
to protein A-sepharose and to iimnunoabsorbents consisting of goat 
antibodies against murine IgGl, IgG2, igA and IgM (obtained frem Meloy, 
Springfield, U.S.A.). 
The amounts of Intact antibody molecules in the final F(ab')2 preparation 
amounted to: IgA < 0.03%; IgM < 0.05%; IgGl < 0.02% and IgG2 < 0.02%, as 
was determined by radial immunodiffusion. 
The amount of protein in the IgG and F(ab')2 preparations was quantitated 
by the method described by Lowry et al. (20). The antigen-binding activity 
of the F(ab')2 molecules was determined by indirect immunofluorescence 
-104-
and equalled that of Intact IgG. In addition, it was shown that F(ab')2 
was able to inhibit specifically the complement-mediated cytolysis of 
B10.D2 spleen cells by intact IgG. 
Tumor transplantation 
The tumor in this study was a mouse fibrosarcoma which was induced in a 
B10.D2 female mouse by a subcutaneous injection of 0.05 ml olive oil 
containing 1 mg 3-methylcholanthrene. The sarcoma had been transferred 
in vivo for three years at the time that the experiments were carried 
out. It is a slowly growing tumor, showing microscopically only few 
mitoses per field (magnification 400 x). The average tumor diameter, 
measured two months after intracutaneous injection of 4 χ 10e cells in 
20 syngeneic recipients, is 16.7 mm. To prepare a fibrosarcoma cell 
suspension, one tumor-carrying B10.D2 mouse was sacrificed and the tumor 
was taken out. The tissue was minced in Ringer's salt solution at 4 С 
and suspended by gently pressing through a fine wire mesh. This suspension 
was left standing for 5 minutes and the supernatant was taken as free 
cell suspension. The cells were pelleted at 250 g for 5 minutes and 
resuspended in Ringer's solution. A sample was stained with Sedicolor 
(MoIter GmbH Heidelberg, W. Germany) and tumor cells were counted in a 
Bürker counting chamber. The cell suspension was then diluted to a 
concentration of 2.5 χ IO7 cells/ml. Aliquote of this suspension containing 
2 χ 106 tumor cells were injected intracutaneously on the right dorsal 
flank of B6AF1 female recipients. Tumor growth was followed macroscopically 
by measurement with calipers during 3 months. 
RESULTS 
Tumor enhanoement 
Enhancement was induced in female В6AFI recipients of B10.D2 sarcoma 
grafts by intraperitoneal injections of alloantiserum on days 0, 2, and 
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4 after transplantation. In this model no macroscopically detectable 
tumor growth is seen unless the recipients are treated with an enhancing 
antiserum. It is shown in Table I that only recipients treated with 
specific anti B10.D2 serum display visible tumor growth in most cases. 
The enhanced tumors grow progressively (fig. 1): the diameters of the 
tumors increase untili the recipients succumb. In the recipients not 
treated with with specific enhancing antiserum no tumor growth is 
observed, not even temporarily. 
Jn vivo activity of F(ab')2 
In this model the in vivo activity of F(ab')2 was tested. To be albe to 
compare the activity of F(ab')2 with IgG we first carried out dose-
response studies with intact IgG. The results in Table 2 show that the 
threshold dose for induction of enhancement by IgG in this system lies 
between 300 and 960 ug. F(ab')2 is a dose of 2200 yg, comparable on a 
molar base to 2700 ug of IgG, was ineffective. The inability of F(ab,)2 
to induce enhancement might be due to the decreased half-life of F(ab,)2 
in vivo (21). 
To exclude this, multiple daily injections were given. The experimental 
protocol and the results are also given in Table 2. The administration 
of a total dose of 17.0 mg (Fab')2 in this way did not induce enhancement 
of tumor growth, while 0.96 mg of IgG induced enhancement in 9 out of 10 
animals, resulting in progressive tumor growth. The total amount of 17 
mg of (F(ab')2 did contain at most 6.8 yg of contaminating IgG, which is 
a factor 44 under a non-effective dose of IgG (i.e. 300 ug). 
DISCUSSION 
In the tumor transplantation model which was developed the enhancing 
activity of antibodies and antibody fragments can be dertermined in a 
clear-cut way, since the effect is an all-or-none phenomenon. In recipients 
that were treated with control sera or non-enhancing fractions, no 
visible or palpable tumors developed. The tumor cells were readily 
mean tumor 
diameter(mm) 
20 
15 
10 
5 
0 
20 í.0 60 80 
days after transplantation 
Fig. 1. Passive enhancement of B10.D2 fibrosarcoma grafts in B6AF1 
recipients by administration of B6AF1 anti B10.D2 serum. 
Recipients were treated with 0.25 ml of B6AF1 anti B10.D2 
serum (0 0), 0.25 ml of B6AF1 anti BIO.BR serum (Δ Δ), 
or 0.25 ml of normal B6AF1 serum (x x) at days 0, 2, and 
4 after transplantation. Each point represents the mean value 
of tumor diameters in 5 animals. 
Δ 
χ 
,—о 
χ χ 
Δ Δ 
χ χ 
TABLE I 
Passive enhanaement of B10.D2 fibrosarcoma grafts in B6AF1 recipients 
by administration of B6AF1 anti B10.D2 serum 
a No. of mice with growing 
Treatment tumors/total number tested 
None 0/9 
Normal B6AF1 serum 0/9 
B6AF1 anti В10.BR serum 0/9 
B6AF1 anti B10.D2 serum 18/25 
B6AF1 recipients were injected i.p. with 0.25 ml of serum on days 0, 
2, and 4 after transplantation. 
TABLE II 
Influenae of B6AF1 canti B10.D2 IgG and F(ab')2 administration on the 
growth of B10.D2 fibrosarcoma grafts in B6AF1 recipients 
a No. of mice with growing 
tumors/total number tested 
100 vg IgG χ 3 0/8 
320 ug IgG χ 3 9/10 
900 vg IgG χ 3 9/10 
3000 wg IgG χ 3 10/10 
720 ug F(ab')2 0/17 
1000 ug F(ab')2 
χ 2 on day 0 0/10 
χ 3 on day 1, 2, 3, 4 and 5 
Unless stated otherwise, B6AF1 recipients were injected i.p. on day 
0, 2, and 4 after transplantation. 
Injections were given with intervals of 6 or 9 hr. 
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accesslble for the mediators of cellular Immunity, as the inoculate 
consisted of a free cell suspension. Presumably tumor growth is too slow 
to form a solid tumor and to overrule in this way the host defense 
mechanisms for even a short period. Inherent to such a system is the 
relatively high dosis of antibody needed to give an enhancing effect. In 
our model the threshold dose lies between 300 and 960 pg, which is at 
least a factor 5 above the threshold dose in a skin allograft model 
(17). To test the enhancing activity of F{ah')2 in this model, a high 
dose therefore should be administered. A dose of 17.0 mg of F(ab,)2, 
however, given in multiple daily injections over a period of 6 days, was 
ineffective (Table 2). This dose exceeds on a molar base the lowest 
enhancing dose of intact IgG (i.e. 960 ug) by a factor 22. 
Our data indicate that administration of F(ab')2 fragments of alloantibodies 
to recipients of mouse tumor allografts does not result in enhancement 
of tumor growth. This finding is contrary to the results of others and 
we believe that contami nations of undigested IgG might explain some of 
the reported results. To exclude any enhancement effects of intact IgG, 
we used a highly purified F(ab')2 preparation in which the amount of 
undigested IgG was negligible. 
It should be noted that the enhancing alloantiserum was raised with 
normal donor strain lymphocytes. It contained antibodies against the К 
and I region determinants of the major histocompatibility complex (MHO. 
The role of antibodies against tumor-specific antigens in this system 
will be the subject of further investigation. To examine the effects of 
such antibodies, an anti-tumor serum must be raised in a syngeneic 
model. 
We conclude from our results that the Fc part of the alloantibody molecule 
is required for the induction of enhancement of mouse tumor allografts. 
This is in agreement with the results that we obtained in a mouse skin 
graft model (19), using a similarly isolated and purified F(ab')2 
preparation. 
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SUMMARY 
Antibodies can influence the fate of transplanted organs or tissues in 
two opposite ways. Graft destruction mediated by antibodies has been 
reported to occur in experimental as well as in clinical transplantation. 
On the other hand, specific suppression of the immune response, leading 
to significant prolongation of graft survival, can be induced by 
administration of antibodies. This protective effect of antibodies, 
called passive enhancement, has thusfar been observed only in experimental 
animal models. 
The aim of this study was to determine the experimental conditions that 
favour the induction of either phenomenon. 
We approached this problem in a mouse skin allograft model in which both 
antibody-mediated graft protection and destruction could be reproducibly 
induced, and in a mouse tumor allograft model, in which graft protection 
led to progressive tumor growth. 
In the first set of experiments we focussed on the specificity of the 
antibodies. In the antisera used, antibodies against K-, D-, and I-
region products are present. It was shown in a previous study that anti 
la antibodies could induce enhancement but lacked any destructive 
activity. The role of anti H-2K and H-2D antibodies in these phenomena 
was not clear. We isolated these antibodies by absorption to and elution 
from donor strain red blood cells and tested their in vitro and in vivo 
activities. It was shown that highly purified anti H-2K or anti H-2D 
antibody fractions could be prepared in this way, which were suited for 
in vivo use. Acute antibody-mediated rejection could readily be evoked 
by administration of both anti H-2K and H-2D antibodies. The results 
showed in addition, that these anti SD (serologically defined) antibodies 
were able to induce enhancement, leading to significant and specific 
prolongation of skin allograft survival. On the basis of this latter 
finding we assumed that anti H-2K or H-2D antibodies could block the 
immune response, similarly to the blocking by la antibodies. This 
blocking of the response to H-2K or H-20 region antigens is in agreement 
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with the recent findings that К, D antigens on their own can give rise 
to an Inmune response without needing the help of antigenic differences 
in the I-region. Our results argue strongly against the earlier hypothesis 
that only I-region antigens are able to trigger the recognition and 
proliferation phase of the immune response, and that K- and D-region 
products serve only as the targets for the Immune attack in the killing 
phase. 
The eventual clinical application of enhancing antibodies will depend on 
the availability of large amounts of antibodies of defined specificity. 
Ά way to prepare such antibody fractions could be provided by affinity 
chromatography. The antigen against which the antibodies are directed is 
inmobilized by chemical coupling to a carrier particle. In our experiments 
we tried to isolate the transplantation antigens against which the B6AF1 
anti B10.D2 alloantiserum is directed by solubilization with NP-40 
detergent from B10.D2 lymphoid cells. The antigens were partly purified 
and coupled to CNBr-actlvated Sepharose. 
By absorption and elution of the alloantiserum, a 30-fold purified anti­
body preparation could be obtained, in which the in vitro and in vivo 
activities were preserved. The results show that, basically, this method 
can be used to isolate antibody fractions from complex sera. However, 
its usefulness largely depends on the feasibility to isolate K, D, or la 
antigens separately from cell surfaces. 
The recently developed myeloma cell-fusion technique should be mentioned 
in this context. Probably this technique will provide a powerful tool in 
the preparation of large amounts of antibodies of defined specificity. 
In earlier reports in the literature it was stated that it should be 
possible to induce enhancement with F(ab')2 fragments of allo-IgG. These 
F(ab'}2 fragments lack the Fc part and are therefore not able to bind 
Clq and activate the classical pathway of the complement system. 
Preparation of F(ab')2 fragments would consequently provide one with an 
enhancing preparation that is not capable of inducing acute rejection. 
We prepared these F(ab')2 fragments from B6AF1 anti BIO.02 IgG and 
tested their in vitro and in vivo activities. The results showed that 
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the antigen-binding capacity of F(ab')2 equalled that of undigested IgG; 
the in vitro complement-dependent cytotoxicity of IgG could be inhibited 
with F(ab')2 fragments, that were non-cytotoxic themselves. 
F(ab')2 also lacked in vivo cytotoxicity: acute rejection of skin allo-
grafts could not be induced by administration of F(ab')2. It was shown 
in addition that it was possible to inhibit the destructive activity of 
intact IgG in vivo by prior administration of F(ab')2 to the recipients 
of skin allografts. 
We were, however, unable to induce prolongation of skin allograft survival 
or protection of tumor allografts by administration of F(ab')2 fragments, 
even when given in high doses over a number of days. Crucial in these 
experiments was the purity of the F(ab')2 fragments used, since it was 
known from earlier studies that minimal amounts of intact IgG can induce 
significant graft protection, resulting in prolonged survival of skin 
grafts. 
It is clear from these findings that the possible applications of F(ab,)2 
fragments in clinical transplantation are drastically diminished. The 
absolute requirement of the Fc fragment for the induction of enhancement, 
that was demonstrated in two different transplantation models, threw new 
light, however, on the mechanism behind this phenomenon. We suppose that 
the Fc dependency of enhancement can be explained best by assuming that 
the enhancing antibodies form immune complexes with antigens released 
from the graft, and that these complexes bind subsequently to the antigen-
recognizing cells. These cells will then be eliminated by Fc dependent 
mechanisms. It was actually shown by others that antigen-antibody 
complexes induced em increase in opsonization of antigen-reactive lymphoid 
cells in the liver of rats. These results show that lymphoid cells that 
have a central place in the recognition phase of the immune response can 
be effectively inactivated by specific Immune complexes and this might 
well constitute the most important mechanism in enhancement. 
Despite intensive investigations there has been made only little progress 
towards the application of enhancement as a tool in clinical immuno-
suppression. There is no firm evidence thusfar that enhancement can be 
induced in man: human recipients of kidney allografts with a positive B-
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lymphocyte cross-match do not display significantly higher long-term 
survival rates than patients with a negative B-cell cross-match. 
There is, on the other hand, no proof that human B-cell antibodies, as 
they axe measured in the cross-matching procedure, are comparable to the 
protective la-antibodies in the murine transplantation models, and it is 
therefore not justified to conclude from these observations that enhancement 
plays no role in clinical transplantation. It remains important to 
investigate the eventual clinical relevance of this form of specific 
immunosuppression, since enhancement would be very advantageous in human 
transplantation. The currently used immunosuppression depends mainly on 
steroid hormones, antimetabolite drugs, and anti-lymphocyte globulin, 
all of which induce nonspecific suppression of the immune response. The 
major risk of this type of suppression is infection with bacterial, 
viral, fungal or protozoan organisas. 
A second harmful side-effect is a ten- to twentyfold increased risk of 
spontaneous malignant tumors. Enhancing antibodies do not have these 
draw-backs, since they exert their function specifically in combination 
with the donor transplantation antigens, and do not cripple the whole 
immune apparatus. 
In the immune response to alloantigens there is apparently an intensive 
cooperation between cells and antibodies. This response is subject to 
several regulatory mechanisms, of which antibody-dependent suppression 
of cellular immunity is only one. Further investigation of this complex 
defense system holds the premise of finding a way of specific immuno-
suppression that would ultimately lead to improved graft prognosis in 
human transplantation. 
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STELLINGEN 
1 Bij het gebruik van preparaten, bestaande uit F(ab')2 fragmenten van 
antilichameη dient men het gehalte aan niet gesplitste antilichamen 
te bepalen en aan te tonen dat bij de gebruikte doseringen de toege­
diende hoeveelheid van deze antilichamen beneden de laagste nog 
actieve dosis ligt. 
2 Tijdelijke toediening van cyclosporine A leidt bij de muis niet tot 
een definitief verlies van het vermogen tot afstoting van een huid-
al lotransplantaat. 
3 Met antisera gericht tegen producten van het H-2L locus kan acute 
afstoting worden geinduceerd. 
4 De bij de muis van nature voorkomende Proteinurie wordt niet veroor-
zaakt door een vergrote doorlaatbaarheid van de glomerulaire basaal-
membraan . 
5 Anti-thymocytenserum opgewekt in een konijn verdient in de klinische 
transplantatie de voorkeur boven een preparaat, opgewekt in een 
paard. 
6 Bepaling van de hoeveelheid paraproteine in humaan serum volgens de 
methode beschreven door Salmon en Smith is alleen mogelijk indien dit 
paraproteine in een elektrisch veld een uitgesproken gamma-mobiliteit 
heeft. 
Salmon, S.E., and B.A. Smith. (1970). J.Clin.Invest. 49:1114. 
7 Voor een adequate diagnostiek van monoclonale gammopathieên is het 
wenselijk dat immunofluorescentie en immunoelektroforeseonderzoek 
naast elkaar in hetzelfde laboratorium plaatsvinden. 
θ Het gehalte aan transferrine in liquor cerebrospinalis stijgt met 
de leeftijd. 
9 Immunologie is in de scheikundestudie ondervertegenwoordigd. 
Het is wenselijk om het volgen vein een bijvakstage in deze richting 
te stimuleren. 
10 Nieuwbouw in kleine kernen hoeft er niet toe te leiden dat de ver-
schillen in stedebouwkundige identiteit tussen de afzonderlijke 
kernen vervlakken. 
11 Een onderwijsbeleid dat gericht is op gelijke kansen in het onder-
wijs is gedoemd te falen zolang de gelijke kansen in de maatschappij 
niet verwezenlijkt zijn. 
J. van Kemenade (1974). Beleidsplan voor het onderwijs 
aan groepen in achterstandssituaties. Staatsuitgeverij, 
's-Gravenhage. 
12 Het beschikken over veel motivatie en minder intelligentie levert 
vaak meer op dan de combinatie weinig motivatie, hoge intelligentie. 
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